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CHAPTER I 
INTRODUCTION 
Neurotrophic factors (NTFs) represent a unique class of 
proteins that are involved specifically in neuronal 
development and the survival. of mature neurons. They also 
exert an important effect on lesion-induced neuronal 
plasticity. These actions of NTFs may provide a key to 
developing pharmacological agents for the treatment of 
neurodegenerative diseases. 
In neurodegenerative diseases such as Senile Dementia 
of the Alzheimer type (SDAT) and Parkinson's disease (PD), 
neurons atrophy, become dysfunctional, and ultimately die. 
In these diseases there is a loss of neurons and their 
associated neurotransmitters from specific regions of the 
brain. In SDAT, cell loss occurs in the basal forebrain 
[medial septum (MS), substantia innominata, hippocampus, 
amygdala], while in PD, neurons in the substantia nigra die. 
This cell loss results in a deficiency of the neurotrans-
mitters acetylcholine (ACh) and dopamine, respectively, in 
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these patients. The loss of cholinergic neurons in SDAT 
patients is thought to be responsible for producing the 
deficits in memory and cognition experienced by these 
patients (Hefti 1994). Since neuronal death occurs in these 
diseases and because NTFs are known to be important in the 
survival of adult neurons, it has been proposed that the use 
of NTFs represents a plausible therapy in the treatment of 
these diseases (Koliatsos et al. 1993; Lindsay et al. 1994; 
Hefti 1994) . 
Recently several NTFs have been isolated including 
Nerve Growth Factor (NGF) , basic Fibroblast Growth Factor 
(bFGF), Brain Derived Neurotrophic Factor (BDNF), Neuro-
trophin-3 (NT-3), and Neurotrophin-4 (NT-4). NGF was the 
first of these to be isolated and has been shown to act on 
several groups of cholinergic neurons located in the basal 
forebrain. One such group of neurons is the septo-
hippocampal pathway (SHP) . In this pathway, the fimbria-
fornix (FF) connects the septum and hippocampus. When the FF 
is surgically transected, there is a loss of cholinergic 
neurons and their associated phenotypic markers (Hefti 1986; 
Lapchak, Araujo, and Hefti 1992) . The similarity in the 
reduction of cholinergic phenotypic markers in the SHP to 
changes in SDAT patients, and its well defined anatomical 
structure, make this pathway an appropriate region to test 
the in vivo effects of NTFs on cholinergic neurons. 
Several studies have evaluated the effects of NGF on 
the loss of cholinergic neurons in the SHP. NGF can reverse 
the loss of choline acetyltransferase (ChAT) immuno-
reacti vity (IR) and acetylcholinesterase (AChE) staining 
induced by transecting the FF (Hagg et al. 1989; Kromer 
1987; Montero and Hefti 1988; Otto, Frotscher, and Unsicker 
1989; Anderson et al. 1988). This work on compromised 
cholinergic neurons in the SHP has led to the proposed use 
of NGF specifically for the treatment of SDAT (Hefti and 
Schneider 1989). 
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Although NGF has been shown to be effective in 
reversing the reduction in cholinergic phenotypic markers 
that occur in FF transected rats, studies investigating the 
effects of NGF on normal cholinergic neurons are not 
conclusive. Some studies indicate that NGF does not affect 
these neurons (Williams, Jodelis, and Donald 1989; Hefti, 
Dravid, and Hartikka 1984). In contrast, other studies have 
demonstrated that NGF does affect normal cholinergic neurons 
of the SHP, although these effects appear to be less than 
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those seen in compromised neuronal systems (Fusco et al. 
1989; Williams 199la). These studies indicate that more work 
is needed in evaluating the effects of NGF on normal, non-
compromised, cholinergic neurons. Furthermore, dose and time 
response experiments of the effects of NGF on normal neurons 
have not been previously conducted and are necessary if NGF 
is to be considered for use as a treatment for SDAT. 
In addition to NGF, two other NTFs have been shown to 
affect cholinergic neurons of the basal forebrain region. 
bFGF, like NGF, has been shown to be capable of reversing 
decreases in cholinergic phenotypic markers in the SHP 
induced by transecting the FF (Otto, Frotscher, and Unsicker 
1989; Anderson et al. 1988). BDNF, a more recently isolated 
NTF (Liebrock et al. 1989), has also been shown to affect 
cholinergic neurons. Much of this work has shown that, in 
culture, BDNF promotes the survival of septal cells. In 
contrast, there are conflicting reports as to whether in 
vivo BDNF administration affects cholinergic neurons (Morse 
et al. 1993; Lapchak, Araujo, and Hefti 1992). 
Although both bFGF and BDNF act on cholinergic neurons 
of the basal forebrain, these two NTFs are not as well 
characterized as NGF. Neither bFGF nor BDNF have been eval-
uated as to their effects on normal cholinergic neurons, in 
vivo. 
Further investigation is needed to determine the 
effects of NGF, bFGF, and BDNF on normal cholinergic 
neurons. A comparison of the effects of these three NTFs on 
normal neurons, as well as on neurons with decreased 
cholinergic phenotypic markers, is important for their 
possible future use as therapeutic agents in the treatment 
of neurodegenerative diseases. Further, the current 
knowledge of NTFs and their effects indicate that 
cholinergic neurons with reduced phenotypic markers may be 
more sensitive to exogenous NTFs than normal neurons. 
The goal of this dissertation was to investigate the 
in vivo effects of various NTFs on both normal and 
compromised cholinergic neurons of the SHP. 
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In these studies, the neurotoxin AF64A (ethylcholine 
aziridinium ion) was used to investigate the effects of NTFs 
on cholinergic neurons with reduced enzyme activity in the 
SHP. AF64A has been shown to produce decreases in 
cholinergic enzyme activity in neurons of the SHP (Fisher et 
al. 1982; El Tamer et al. 1992). AF64A is selective for 
cholinergic neurons of the SHP and provides a more specific 
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method of decreasing cholinergic phenotypic markers than FF 
transection. Therefore, AF64A represents a novel approach to 
evaluating whether cholinergic neurons, whose activity has 
been altered, are more sensitive to exogenously administered 
NTFs than normal (non-compromised) neurons. 
The following hypotheses were tested in this work: 
1) Exogenous NTFs, when administered in vivo to adult rats, 
stimulate ChAT and AChE activity in normal cholinergic 
neurons. 
2) When alterations in neuronal cholinergic enzyme activity 
are created by AF64A, the affected neurons have an 
increased sensitivity to exogenous NTF administration. 
These hypotheses have allowed the following questions to be 
addressed: 
1) Do various NTFs affect the enzyme activity of normal 
cholinergic neurons in the SHP? What is the dose and time 
relationship between NTF administration and changes in 
cholinergic enzyme activity? Are they the same for all 
the NTFs or are they different? 
2) Are the changes in enzyme activity selective for 
cholinergic neurons or do they also occur in other 
neurotransmitter systems? 
3) Does AF64A treatment increase the sensitivity of 
cholinergic neurons of the BHP to exogenous NTFs? 
Specific Aims 
Two specific aims were addressed in this project. 
Specific Aim # 1: 
EFFECT OF INTRACEREBROVENTRICULAR ADMINISTRATION OF 
NTFs ON NORMAL CHOLINERGIC NEURONS OF THE SEPTO-HIPPOCAMPAL 
PATHWAY. 
la) Determine if NTFs (NGF, bFGF, BDNF), when administered 
intracerebroventricularly (i.c.v.), affect cholinergic 
neurons in the BHP of normal rats. 
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In order to evaluate the effects of these trophic 
factors on cholinergic neurons, the levels of ChAT and AChE 
activity in the SHP were measured after i.c.v. adminis-
tration of the three NTFs. Dose response studies for NGF and 
BDNF were conducted. Further, the time course relationship 
between NGF administration and changes in cholinergic enzyme 
activity in normal rats was examined. 
lb) Determine if NTFs (NGF and BDNF) , when administered 
i.c.v., affect non-cholinergic neurons in the SHP of normal 
rats. 
In order to evaluate the selectivity of NTFs for 
cholinergic neurons, their affect on glutamic acid 
decarboxylase (GAD) activity in the SHP was measured. 
S~ecific Aim# 2: 
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THE IN VIVO EFFECT OF AF64A TREATMENT ON THE ABILITY OF 
NTFs TO AFFECT CHOLINERGIC NEURONS OF THE SEPTO-HIPPOCAMPAL 
PATHWAY. 
Determine if AF64A treatment prior to NTF administra-
tion influences the effects that NTFs have on cholinergic 
enzyme activity in the SHP. 
The NTFs were administered after i.c.v. injection of 
AF64A and cholinergic enzyme activity was measured. 
Concurrently, NGF's effect on cholinergic enzyme activity in 
striatal tissue was measured. This allowed for the 
comparison of the effects of NGF in two populations of 
cholinergic neurons, one which is sensitive to AF64A (the 
SHP) and one which is not {the striatum) . 
CHAPTER II 
LITERATURE REVIEW 
Neurotrophic Factors 
NTF proteins are known to be important in the 
development and maintenance of neurons. Several of these 
NTFs (BDNF, NT-3, and NGF) are known to have up to 50% amino 
acid sequence homology and comprise a family of NTFs called 
neurotrophins (Lapchak, Araujo and Hefti 1992). Although 
similar in structure, they are thought to exert selectivity 
by binding to distinct receptors. In addition to the 
neurotrophins, other proteins such as bFGF, which are not 
similar in structure, also have trophic actions on the 
neurons in the CNS. 
Nerve Growth Factor 
Nerve growth factor was the first trophic factor to be 
discovered and is the prototypical NTF. NGF is a polypeptide 
which is found in the CNS as well as in a limited number of 
9 
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non-neural tissues such as the mouse submaxillary gland 
(Ayer-Lelievre et al. 1983). NGF is a precursor molecule 
which is cleaved to a final, 118 amino acid protein with 6 
cystine residues f orrning three disulfide bonds (Angeletti 
and Bradshaw 1991) . NGF is composed of two a, one ~' and one 
y subunit (Young et al. 1988). The~ subunit (2.5 S) is the 
biologically active portion of the peptide (Lapchak, Araujo 
and Hefti 1992; Varon et al. 1988). 
Although NGF was initially thought to be important in 
neuronal development, it now appears that NGF's main role is 
in the survival and maintenance of neurons. This is in-
dicated by the temporal expression of NGF messenger ribo-
nucleic acid (mRNA) and receptors. As early as postnatal day 
one, immunoreactivity for NGF receptors is found in the 
hippocampus, MS/diagonal band complex (DBC), and striatum 
with peak values found at postnatal day 10 followed by a 
subsequent reduction to adult levels (Koy and Loy 1989). 
Complementary to NGF receptor expression, NGF mRNA in the 
hippocampus follows a similar pattern. On postnatal day two, 
expression is low but increases to adult levels by postnatal 
day 20. These temporal sequences of expression indicate that 
NGF is primarily important for the survival of mature 
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neurons (Lauterborn et al. 1994a). 
Immunoreactivity for NGF in the adult is found in areas 
with large populations of cholinergic neurons such as the 
cerebral cortex, MS/DBC, hippocampus and striatum (Senut et 
al. 1990; Mufson et al. 1994; Alberch et al. 1991). Further, 
NGF mRNA expression follows a similar regional pattern with 
high levels of expression in the hippocampus and cortex 
while low levels occur in the septum and striatum (Lauter-
born et al. 1994a; Shelton et al. 1986; Korsching et al. 
1985). Regional differences in the expression of NGF are 
found within the hippocampus. The highest levels are seen in 
the dentate gyrus and cornu Ammonis (CA)3-4 regions while 
lower levels are found in the CAl-2 regions (Lauterborn et 
al. 1994a; Korsching et al. 1985). The distribution of NGF-
IR and mRNA is consistent with the idea that NGF is a 
target-derived trophic factor, since one would expect a high 
level of NGF-IR in the MS/DEC and the hippocampus but only 
high levels of the mRNA in the hippocampus. 
The expression of NGF and its mRNA in the brain is 
responsive to changes in neuronal activity. Activity induced 
by excitatory amino acids increases endogenous expression of 
NGF in the hippocampus (Gall et al. 1991). Further, 
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electrolytic lesions produce an increase in hippocampal NGF 
mRNA (Gall et al. 1989), NGF-like-IR and NGF activity (Scott 
et al. 1994). NGF levels are also increased in both the 
hippocampus (95%) and septum (250%) after the FF is 
transected (Weskamp et al. 1986). 
Increases in endogenous NGF may also be due to 
stimulation of cholinergic neurons. Quisqualate 
administration (which produces excitation) into the MS/DBC 
produces an increase in NGF mRNA in the hippocampus. This 
increase can be blocked by the cholinergic antagonist, 
scopolamine (Lindefors et al. 1992) and indicates that 
cholinergic neuronal activity in this region may regulate 
NGF expression. 
NGF acts via a postsynaptic receptor which has both a 
high and low affinity component. It is now recognized that 
there are two receptors which bind NGF. One is the high 
affinity receptor called TrkA (pl40) (Kd-10-11M) and the 
other is the low affinity receptor, p75 (Kd-10- 9M) . TrkA is 
formed from the proto-oncogene trk (Kaplan et al. 1991) and 
is a 140 KD membrane spanning protein specific for NGF. 
Further, it is TrkA which is responsible for the biological 
activity induced by NGF (Lapchak et al. 1992; Varon et al. 
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1988). TrkA is a tyrosine kinase receptor (Kaplan et al. 
1991) and therefore stimulation with NGF produces auto-
phosphorylation of the tyrosine residues. This auto-
phosphorylation contributes to producing the response seen 
in neurons treated with NGF and can be blocked by the kinase 
inhibitor K252a (Maher et al. 1989). 
The regional localization of the NGF receptor is 
similar to that of the NGF protein and its mRNA. In adult 
rats, NGF receptors have been colocalized by immuno-
cytochemistry with cholinergic neurons in the MS/DBC, 
striatum and hippocarnpus (Koy and Loy 1989; Hagg et al. 
1989; Mufson et al. 1994; Taniuchi et al. 1986; Woolf, Gould 
and Butcher 1989) . NGF receptor immunoreactivity has 92% 
colocalization with ChAT positive neurons in the basal 
forebrain (Woolf, Gould and Butcher 1989). 
After binding to the receptor, NGF is transported in a 
retrograde manner (Ferguson et al. 1991; Taniuchi et al. 
1986) . If usI-NGF is injected into the lateral ventricle, 
the MS/DBC becomes reactive. Peak reactivity occurs 18 hours 
post injection but traces of the isotope in the MS/DBC can 
be seen as early as five hours. The binding and accumulation 
of NGF into the MS/DBC region is specific since the addition 
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of an excess amount of cold NGF inhibited this binding and 
transport. Further, NGF is rapidly cleared from the brain by 
30 hours after i.c.v. injection. (Ferguson et al. 1991). 
Although NGF's action is mediated via receptor binding, 
its intracellular mechanism of action is still unknown. One 
possible mechanism may be through second messengers. In 
vitro work has demonstrated that NGF stimulates a variety of 
second messengers such as calcium (CA2~) (Alonso et al. 
1986), cAMP or inositol triphosphate (Knipper et al. 1993). 
In addition it appears that the immediate early gene, c-fos, 
may also play a role. When exogenous NGF is administered to 
neurons, c-fos expression increases (Kruijer et al. 1985). 
Administration of exogenous NGF can alter cholinergic 
markers in rats with neuronal injury. Transection of the FF 
has been used extensively to create reductions in choliner-
gic phenotypic markers in BHP neurons. Transection of the FF 
results in a reduction of ChAT and AChE (=50-80%) in both 
the MS and hippocampus (Lapchak and Hefti 1991; Hefti 1986; 
Armstrong et al. 1987; Matthews et al. 1987; Gage et al. 
1988) . Exogenously applied NGF into the lateral ventricle 
can almost completely attenuate the loss of these 
cholinergic phenotypic markers (up to 70% sparing of 
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neurons) (Hagg et al. 1989, Kromer 1987; Montero et al. 
1988; Gage et al. 1988) and produces a hypertrophic response 
in the size of MS cells (Vahlsing et al. 1991). 
Williams, Jodelis, and Donald (1989) have shown that 
normal, unaltered, cholinergic neurons in the septum of 
normal rats do not respond to exogenous NGF, while those in 
animals with complete FF transections appear to be 
"supersensitive" to NGF. NGF, in FF transected rats, 
increased ChAT activity 200% higher then in normal animals. 
Furthermore, a similar effect on ChAT activity has been 
found in animals that have had partial FF transections 
(Hefti Dravid and Hartinkka 1984i Gage et al. 1988). 
Surprisingly, it has been shown that AChE activity is 
unaffected by NGF in the septum of either transected or 
non-transected animals (Williams, Jodelis and Donald 1989; 
Hefti 1986) . 
In contrast, other studies indicate that normal, 
unaltered, cholinergic neurons in the MS/DBC of adult rats 
are responsive to exogenously applied NGF. Fusco et. al, 
(1989) have shown that NGF administration to intact rats 
increases ChAT activity in the MS (79%) and hippocampus 
(43%) in a dose dependent manner. Similar to previous 
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reports (Williams, Jodelis and Donald 1989), NGF did not 
change AChE activity in either of these regions. In addition 
to increasing ChAT activity in the SHP of normal rats (Fusco 
et al. 1989; Vantini et al. 1986; Williams and Rylett 1990), 
NGF also increases high affinity choline transport (HAChT) 
in the hippocampus (Williams and Rylett 1990) . 
Brain Derived Neurotro~hic Factor 
Unlike NGF, BDNF has only recently been isolated and 
cloned (Barde et al. 1982; Leibrock et al. 1989). BDNF is 
similar in structure to NGF, and their amino acid sequences 
show a high degree of homology including a group of six 
cystine residues (Leibrock et al. 1989). Like NGF, BDNF is a 
basic protein (pI~l0.1) with 112 amino acids and a molecular 
weight of approximately 12.3 kDa (Barde et al. 1982). 
The expression of BDNF appears to be specific to 
neuronal tissue since it is not expressed in peripheral 
tissue such as kidney, lung, liver, heart, muscle, and 
spleen (Leibrock et al. 1989). Within the brain, BDNF mRNA 
has been localized to several specific regions including the 
hippocampus, piriform cortex, hypothalamus, cerebellum, 
olfactory nucleus, claustrum, temporal cortex, basolateral 
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amygdala, and the pars compacta of the substantia nigra 
(Phillips et al. 1990; Wetmore et al. 1990; Ernfors et al. 
1990a; Boatell et al. 1992). BDNF mRNA appears to be highest 
in the hippocampus, where the largest level of expression 
occurs in the pyramidal cell layer of CAl-4, the hilus, and 
the granular cells of the dentate gyrus (DG) (Ernfors et al. 
1990a; Phillips et al. 1990; Wetmore et al. 1990; Boatell et 
al. 1992). The expression of BDNF mRNA appears to be 
mediated by neuronal activity. Hilar lesions and adminis-
tration of excitatory amino acids can increase the level of 
BDNF mRNA expression in the hippocampus (Zafra et al. 1990; 
Isackson et al. 1991; Ballarin et al. 1991; Boatell et al. 
1992). This up-regulation in expression appears to be 
modulated by cholinergic neurons. It has been shown that the 
muscarinic receptor agonists, pilocarpine or carbachol 
produce increases in BDNF mRNA expression while the 
antagonists, scopolamine or atropine, can block these 
effects (Berzaghi et al. 1993; Zafra et al. 1990). 
BDNF binds to a specific, 145 kd, glycoprotein 
receptor, TrkB. Like the TrkA receptor, TrkB is a tyrosine 
kinase receptor and is therefore capable of phosphorylating 
tyrosine residues on proteins. trkB mRNA is localized to 
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specific regions of the brain including the diencephalon, 
hypothalamus, basal ganglia, basal forebrain, hippocampus 
(pyramidal and granule layers), substantia nigra, amygdala, 
neocortex (II-VI) (Altar et al. 1994c), choroid plexus, 
ependymal cells of the ventricles, and glial cells (Yan et 
al. 1994). Immunohistochemical studies indicate that trkB is 
localized in the wall of the lateral ventricle, choroid 
plexus, pia mater, and cells in the parenchyma (Yan et al. 
1994). 125 I-BDNF binds to cortex, septum, hippocampus, 
cerebellum and the walls of the lateral ventricle (Altar et 
al. 1994c; Yan et al. 1994). This localization of the trkB 
receptor is similar to that of BDNF mRNA or its protein and 
therefore the receptor and BDNF are probably coexpressed 
(Kokaia et al. 1993). Although BDNF does not bind to the 
high affinity NGF receptor (trkA) it does appear to bind to 
the low affinity (p75) receptor. This binding is not 
necessary for the action of BDNF and is thought to be due to 
the similarities in amino acid sequences between BDNF and 
NGF. 
Although BDNF is not as well characterized as NGF, 
studies have been conducted both in vitro and in vivo in 
order to determine the action of BDNF on neurons. In 
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culture, BDNF has been shown to affect cells from various 
brain regions. This is not unexpected since BDNF, unlike 
NGF, is widely distributed in the brain. In vitro survival 
of cortical neurons appears to be due to the action of BDNF. 
When antibodies to BDNF are introduced into the culture, 
cell atrophy occurs, survival decreases and there is a loss 
of dendritic branching (Ghosh et al. 1994). When BDNF is 
applied to cultures of basal forebrain cells, their survival 
as well as production of cholinergic phenotypic markers 
(ChAT, AChE, and HAChT) increases (Alderson et al. 1990; 
Nonomura and Hatanaka 1992}. The action of BDNF is not 
limited to cholinergic neurons; it also promotes tyrosine 
hydroxylase staining in 6-hydroxydopamine (6-0HDA) or N-
methyl-4-phenylpyridinium ion (MPP+) treated mesencephalic 
neurons (Spina et al. 1992). 
Recently, work has been conducted to investigate BDNF's 
effect in vivo in rats. BDNF has been shown to prevent the 
effects of FF transection on cholinergic neurons in the 
septum when administered intraseptally (Morse et al. 1992, 
1993) or by i.c.v. injection (Knusel et al. 1992). In 
contrast, other work has demonstrated that BDNF does not 
restore phenotypic markers of cholinergic activity (ACh, 
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ChAT activity, HAChT, ChAT-IR) in the septum after FF 
transection (Lapchak et al. 1992; Koliatsos et al. 1994). 
BDNF also does not affect cholinergic markers in the nucleus 
basalis of Meynert (nbM) or cortex after lesion of these 
areas (Skup et al. 1994; Dekker et al. 1994). From these 
current reports, BDNF may or may not act on cholinergic 
neurons in vivo. The differences found in the effects of 
this NTF may be accounted for by its distribution when 
administered. Work with 1251-BDNF has shown that when 
injected into the lateral ventricle, BDNF binds to the 
ependymal layers whereas when administered intraseptally, it 
is localized to the dorsal septum near the injection site 
(Morse et al. 1993). This would make sense since the trkB 
receptor is also localized to the ependymal cells that line 
the wall of the lateral ventricles. Such findings indicate 
that BDNF may play a role in the functioning of cholinergic 
neurons of the SHP. 
BDNF administration to other regions of the brain 
indicates that cholinergic neurons may not be the only 
populations of neurons affected by BDNF. Supranigral 
administration of BDNF to 6-0HDA lesioned rats attenuates 
behavioral impairments and the reduction of dopaminergic 
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metabolites that occur in these animals (Altar et al. 
1994b) . 
Fibroblast Growth Factor 
Fibroblast growth factor is a neurotrophic factor 
that occurs in basic and acidic forms. Of these two forms, 
the action of basic fibroblast growth factor (bFGF) on the 
brain has been studied in greater detail. Unlike NGF, bFGF 
has a more ubiquitous distribution in the brain. Basic 
fibroblast growth factor mRNA has been localized to the 
cortex, septum, hippocampus, olfactory bulb, superior and 
inferior colliculus and pituitary (Ernfors et al. 1990a; 
Powell et al, 1991; Riva et al. 1994). This expression is 
similar to the immunoreactivity for the bFGF protein. 
Matsuyama et al. (1992) reported that bFGF-IR is found in the 
cerebellum, red nucleus and reticular formation, cortex, 
olfactory bulb, septum, DBC, and hippocampus. Within the 
hippocampus, the granule cells of the dentate gyrus and 
pyramidal cells in the CA2-3 regions have the highest levels 
of bFGF-IR (Matsuyama et al. 1992; Gomez-Pinilla et al. 
1992) . 
In agreement with the localization of bFGF mRNA and its 
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protein, mRNA for the bFGF receptor is also localized to the 
cortex, hippocampus, brain stem and cerebellum (Wanaka et 
al. 1990). Surprisingly the regional expression in the 
hippocampus of the bFGF receptor mRNA is different from that 
which is found for the bFGF protein. The receptor mRNA is 
more highly concentrated in the CA3-4 regions while the DG 
and CAl, CA2 regions have a lower level of mRNA expression 
(Wanaka et al. 1990; Gomez-Pinilla et al. 1992). This 
regional expression of bFGF receptor mRNA agrees with the 
binding characteristics of 1251-bFGF when administered into 
the ventricles. The usr-bFGF binding is localized to the 
cortex, hippocampus (pyramidal cells of the CAl-3 regions) , 
thalamic nuclei and hypothalamus. Surprisingly, no labeling 
was found in the basal forebrain region (Ferguson et al. 
1991). 
The expression of bFGF in the brain appears to be 
developmentally regulated. Basic fibroblast growth factor 
mRNA reaches its peak expression in the brain at embryonic 
day 16 and then decreases to its adult level (Ernfors et al. 
1990b) . The bFGF receptor mRNA follows a similar pattern and 
is most highly expressed at embryonic days 13-17 before it 
decreases to adult levels (Powell et al. 1991). 
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Although bFGF is expressed endogenously in the brain, 
this expression can be regulated or modified. Like other 
trophic factors, neuronal activity appears to be a mediator 
of endogenous expression. Rats which received electroshock 
showed an increase in bFGF mRNA expression in the 
hippocampus, olfactory bulb, cerebellum and entorhinal 
cortex (Follesa et al. 1994). Further, chemical agents, such 
as kainate, which induce neuronal activity also increase the 
neuronal expression of bFGF. Intraperitoneal injection of 
kainate into rats increased expression of bFGF mRNA, bFGF 
and its receptor in the hippocampus (Riva et al. 1994; Van 
Der Wal et al. 1994). Increased endogenous expression of 
bFGF and its associated proteins may be due to increased 
production from astrocytes, since bFGF and its associated 
proteins correlate with glial f ibrillary acidic protein 
staining (Gomez-Pinilla et al. 1992) in these regions. 
Basal forebrain cholinergic neurons are known to be 
stimulated by exogenously applied bFGF. Basic fibroblast 
growth factor administration to septa! cell cultures 
increases ChAT activity, AChE staining and cell density 
(Knusel et al. 1990; Kushima et al. 1992). These increases 
are specific for bFGF since they can be blocked by selective 
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antibodies (Knusel et al. 1990). 
In parallel with the in vitro work done, in vivo bFGF 
administration indicates that this NTF is important in the 
maintenance of cholinergic neurons in the MS/DBC and their 
recovery after FF transection. Like NGF, when bFGF is 
administered after FF transection, ChAT-IR, AChE staining, 
and cell survival in the MS/DBC is increased compared with 
controls (Otto et al. 1989; Anderson et al. 1988). Exogenous 
bFGF also reduces the loss of NGF receptor positive neurons 
in the MS/DBC from 60% to only 25~ (Gomez-Pinilla et al. 
1992; Schwaber et al. 1991). Further, bFGF attenuates the 
loss of ChAT activity seen in the hippocampus (Barette et 
al. 1989; Araujo et al. 1993) but, in contrast to the work 
with NGF, does not alter the loss of other presynaptic 
cholinergic markers such as the synthesis and release of ACh 
(Araujo et al. 1993). Exogenously applied bFGF can also 
reverse the loss of tyrosine hydroxylase staining that 
occurs within the striatum after the neurotoxin, 1-methyl-4-
phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) is administered 
(Otto et al. 1990). This, as well as the regional 
distribution of bFGF, indicates that bFGF may not be as 
selective as NGF for cholinergic neurons but may act on 
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other neurotransmitter systems as well. 
Anatomy of the Septo-Hippocampal Pathway 
The septo-hippocampal pathway originates from the 
septal nucleus/DEC (vertical and horizontal limb) which 
projects via the fimbria fornix to the hippocampal formation 
(Butcher and Woolf 1986) . The main neurotransmitters found 
within this pathway are ACh and y-aminobutyric acid (GABA), 
(Leranth et al. 1992; Witter 1986) although other 
neurotransmitters, such as norepinephrine, serotonin and 
dopamine are also present (Hortnagl et al. 1991). 
Acetylcholine is synthesized from the precursor choline 
and acetyl Coenzyme A by the enzyme ChAT (Taylor and Brown 
1989). ChAT is synthesized in the septal cell bodies as 
demonstrated by the localization of its mRNA to this region 
(Ibanez et al. 1991; Lauterborn et al. 1993). ChAT is 
located throughout the entire neuron since it is transported 
to the terminal region in the hippocarnpus where it 
synthesizes ACh. ACh is metabolized in the synaptic cleft by 
the enzyme AChE into choline and acetic acid. Choline is 
transported into the cell terminal by sodium dependent 
HAChT. The level of choline and its uptake into the neuronal 
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terminal represents the rate limiting step in the production 
of ACh (Taylor and Brown 1989) . The neurochemicals 
associated with the cholinergic neurons are useful markers 
for determining the anatomical distribution of neurons which 
express ACh. 
GABA is an inhibitory neurotransmitter and plays a role 
in the regulation of neuronal activity. GABA is synthesized 
from L-glutamic acid by the enzyme GAD and the cofactor, 
pyridoxal-5'-phosphate, in the terminal (McGeer and McGeer 
1989) . GAD is located in the synaptosome of neurons and its 
restriction to GABAergic neurons make it a reliable marker 
for GABA (Martin and Rimvall l993; Storm-Mathisen 1978). The 
activity of GABA is stopped by either sodium dependent 
uptake or the enzyme, GABA transaminase. As in the case of 
cholinergic neurons, the neurochemicals of the GABAergic 
neurons are used as anatomical and functional markers for 
these neurons. Further, parvalbumin is also used to 
determine the location of GABAergic neurons since it has 
been shown to be colocalized with GABA in the SHP (Freund 
1989). 
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The Septal Region 
The subcortical septal area consists of four main 
regions: 1) lateral; 2) medial; 3) ventral; and 4) posterior 
(Swanson 1978). The lateral region can be further separated 
into dorsal, intermediate and ventral areas and is comprised 
of medium size neurons. The medial region consists of two 
sub-areas, the medial septal nuclei and diagonal band 
complex. These nuclei are made up of both small and large 
neurons. The ventral region mainly consists of the bed 
nucleus of stria terminalis and is composed of a population 
of large heterogenous neurons. Finally the posterior region 
consists of two cell groups, the septo-fimbria and 
triangular nuclei (Swanson 1978). 
In the MS/DBC region, neurons are immunoreactive for 
both ChAT (Amaral and Kurz 1985) and parvalbumin (Kiss et al 
1990; Leranth et al. 1992). Further, they exhibit both ChAT 
and GAD activity (Fonnum 1977) . These two markers are not 
colocalized in the same neurons. Parvalbumin positive 
neurons are predominantly located in the intermedial portion 
of the medial septum while CbAT positive neurons are located 
laterally. In contrast to the septum, with its localized 
concentration of parvalbumin staining, the parvalbumin 
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positive cells in the DBC are widely scattered (Kiss et al. 
1990; Freund 1989). 
The Hippocampal Region 
The hippocampal formation can be divided into several 
regions. These include the CA, DG, and subiculum. These 
regions have a laminar organization which is defined by 
three distinct cell layers. The cellular organization in the 
CA region is composed of the molecular layer (small 
neurons), pyramidal layer (large neurons), and polymorphic 
layer. The DG cellular organization is similar, with the 
exception of the pyramidal layer which is replaced by a 
granular layer (small neurons) (Witter 1986) . The CA region 
and the subiculum form part of the pre- and post-
commissural segments of the fornix system, while the DG 
gives rise primarily to intra-hippocampal connections. 
The hippocampus expresses both ChAT (Reine et al. 1992) 
and GAD activity (Reine et al. 1992; Martin and Rimvall 
1993; Hortnagl et al. 1991). The ChAT activity probably 
originates in the septum since ChAT mRNA is undetectable in 
the hippocampus (Ibanez Ernfors and Persson 1991; Lauterborn 
et al. 1993). It is possible that cholinergic interneurons 
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also contribute to the level of ChAT activity in the 
hippocampus since ChAT-IR is seen in this region (Wainer et 
al. 1985; Matthews et al. 1987). In addition to GAD 
activity, hippocampal neurons are also immunoreactive for 
the GAD protein (Brady and Vaughn 1988; Reine et al. 1992) 
Septo-hippocampal Pathway Connections 
Many studies have been conducted to investigate the 
innervation between the septal/DBC and the hippocampal 
formation. Fibers from the MS/DBC have been shown to 
terminate in various regions of the dorsal hippocampus 
including the infragranular and granular layers of the 
dentate gyrus, CA3-4 regions, and the molecular layer of the 
subiculum (Witter 1986; Rose, Hattori, and Fibiger 1976; 
Baisden , Woodruff, and Hoover 1984; Amaral and Kurz 1985). 
The ventral hippocampus receives fibers from the lateral 
portion of the MS and dorsolateral portion of the DBC. These 
connections are both cholinergic (Toth 1993; Wainer 1985; 
Okayama et al. 1987) and GABAergic (Leranth 1992) as 
indicated by retrograde labeling with horseradish 
peroxidase, cholinergic and GABAergic markers. Even though 
these neurons express different neurotransmitters, they are 
similar in structure and morphological characteristics 
(Naumann, Linke, and Frotscher 1992) . 
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The SHP is a reciprocal pathway with the hippocampus 
projecting back to the septum. The topography of this 
reciprocal innervation includes the pyramidal cells in the 
CAl, CA3, and subiculum regions of the dorsal hippocampus 
projecting to the dorsomedial lateral septal nuclei. The 
ventral hippocampus projects to the ventrolateral portion of 
the lateral septum (Witter 1986; Leranth et al. 1992). These 
projections are thought to be primarily ipsilateral, but a 
small component is bilateral. A large percentage (94%) of 
antrogradely labeled neurons in the medial and lateral 
septum are immunoreactive for GABA (Toth et al. 1993). These 
afferents have connections with both parvalbumin and ChAT 
positive neurons (Toth et al. 1993). 
Senile Dementia of the Alzheimer Type (SDAT) 
Symptoms and Clinical Criteria 
Dementia due to Alzheimer's disease represents 
approximately 50% of all clinically defined cases of 
dementia (Blennow and Wallen, 1994) . The prevalence of SDAT 
has increased over recent years due to the overall aging of 
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the general population. Currently, 10-15% of the population 
over age 65 will be diagnosed as having SDAT {Bondareff 
19 94) . 
Patients present a host of symptoms which imply, but do 
not definitively diagnose, that they have SDAT. The 
classical symptoms of SDAT include loss of memory, reduced 
cognitive abilities, and changes in personality. Although a 
definitive diagnosis is not possible until death, criteria 
have been established to make a diagnosis of probable SDAT. 
These criteria, formulated by the National Institute for 
Neurological and Communicative Disorders and Stroke, are: 
dementia {determined by clinical exam and neuropsychological 
test) with deficits in two or more areas of cognition, 
progressive worsening of memory and cognition, no 
disturbance in consciousness, and onset after age 65. 
Further these symptoms must occur in the absence of systemic 
disorders and other brain diseases that would cause changes 
in cognition and memory (McXhann et al. 1984). Early in the 
disease the dementia is mild and patients continue to live 
independently. As the dementia becomes more pronounced, 
patients can no longer live independently and require 
chronic care. The life expectancy in patients with SDAT is 
usually 5-6 years less than that of the general population 
(Blennow and Wallen, 1994). 
Neuropathology 
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At present, the only definitive diagnosis of SDAT 
occurs after the patient dies and a histopathological 
examination can be made (McKhann et al. 1984). Several 
neuropathological features, which were originally 
characterized by Alois Alzheimer in 1907, remain the most 
positive means of establishing whether a patient had SDAT. 
One of these is the abnormal accumulation of proteins which 
form neuritic plaques and neurofibrillary tangles (Hefti and 
Mash 1989; Glenner 1989). The plaques and tangles accumulate 
primarily in the cortex, amygdala, and hippocampus regions 
of the brain (Cordell 1994). 
Neuritic plaques are formed from an accumulation, in 
the parenchyma of neurons, of a 39-42 amino acid protein 
known as ~-amyloid. This protein is produced from a 
precursor known as the amyloid precursor protein (APP) When 
the APP is cleaved it can produce either a soluble (via a 
secretase enzyme) or a non-soluble (via a lysosome pathway) 
form of ~-amyloid (Hardy and Higgins 1992; for review see 
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Cordell 1994). Since ~-amyloid is also produced in people 
without SDAT, it has been postulated that SDAT patients have 
a predisposition to accumulate the non-soluble form of the 
protein. 
The neurofibrillary tangles are made up of paired 
helical filaments which are composed of the protein, tau 
(Kosik et al. 1992). These filaments are thought to be 
formed through an abnormally high level of phosphorylation 
of the protein, Tau. Recent evidence that this 
phosphorylation may be due to the ~-amyloid which is co-
expressed with the tangles. In vitro, ~-amyloid induces 
abnormal phosphorylation of the tau protein in cortical and 
hippocampal tissue (Cordell 1994). 
Although both plaques and tangles have been well 
described, why these distinct features occur in the brains 
of SDAT patients is uncertain. Further, whether these 
phenomena represent the cause of the disease, or are a 
consequence of some previous event in the cascade of this 
disease is still unknown. 
In addition to the plaques and tangles associated with 
SDAT, a large amount of neuronal loss also occurs in select 
regions of the brain. This loss occurs from the nbM, MS, and 
hippocampus located in the basal f orebrain region 
(Whitehouse et al. 1982; West et al. 1994) SDAT patients 
have up to a 79% cell loss in these regions (Whitehouse et 
al. 1982). The neuronal loss represents a decrease of 
cholinergic neurons in these regions and a loss of ACh in 
the terminals of these neurons. A reduction in the 
cholinergic markers, ChAT, AChE, and HAChT has been 
demonstrated in the hippocampus, frontal cortex, and 
substantia innominata of patients with SDAT (Nagel et al. 
1983; Davies and Maloney 1976; Rylett, Ball, and Colhoun 
1983; Giacobini 1990; Hefti and Mash 1989). Although this 
neuronal loss is primarily of cholinergic neurons, markers 
for other neurotransmitters, such as norepinephrine, GABA, 
serotonin, dopamine and glutamate (Glenner 1989) also 
decrease in Alzheimer patients. 
Animal Models 
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One of the problems in Alzheimer's research is the lack 
of an appropriate animal model for SDAT. Many investigators 
have endeavored to mimic the loss of cholinergic neurons of 
the basal forebrain in animals. This has been attempted by 
either surgical transection or the use of chemical toxins. 
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When the FF is surgically transected there is a loss of 
neurons in the MS as well as a decrease in cholinergic 
phenotypic markers from the entire SHP (Montero et al. 1988; 
Hagg et al. 1989). Lesioning the nbM-cortical pathway also 
results in neuronal loss and decreases in cholinergic 
neurons (Santucci et al. 1993). 
The reduction of cholinergic phenotypic markers in 
basal forebrain neurons has also been attempted with various 
chemicals which are toxic to these neurons. When excitatory 
amino acids are administered into the brain, they have been 
shown to produce neuronal destruction (Santucci, Kanof, and 
Haroutunian 1993; Unger and Schmitt 1992). One problem with 
using excitatory amino acids is that the neuronal loss 
produced is non-specific. In addition to cholinergic 
neurons, other neuronal types are also decreased. 
In contrast to the non-specific damage caused by 
excitatory amino acids, the neurotoxin AF64A (ethylcholine 
mustard aziridinium) produces a more selective reduction in 
cholinergic phenotypic markers in the SHP. These include the 
loss of cholinergic markers such as ChAT, AChE and HAChT 
activity (El Tamer et al. 1992), as well as a loss of ChAT 
positive cells in the medial septum (Lorens et al. 1991). In 
addition to the reduction of cholinergic markers, animals 
treated with AF64A also demonstrate behavioral changes and 
memory deficits (Chrobak et al. 1987). 
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Aged rats show some anatomical and neurochemical 
changes similar to SDAT patients. They have neuronal atrophy 
and cell loss as well as a reduction in basal forebrain 
cholinergic markers (Mervis et al. 1991; Williams and 
Rylett, 1990). Further these rats show memory deficits when 
tested on behavioral tasks. In contrast to SDAT patients, 
aged rats do not develop plaques and tangles and therefore 
are not an ideal model. 
Since models of reduced cholinergic function do not 
mimic the plaques and tangles seen in SDAT, investigators 
have tried to mimic these neuropathological signs by 
injecting ~-amyloid directly in the brain of rats. ~-amyloid 
has been shown to be toxic to neurons both in vitro and in 
vivo. In vitro, administration of the ~-(1-40) segment of 
APP produced a decrease in the survival of hippocampal 
neurons (Yankner et al. 1990). When this same fragment was 
injected into either the cortex or hippocampus, neuronal 
loss and neuritic degeneration were produced (Kowall et al. 
1991). Further, in vivo infusion of ~-(1-40) into the 
cerebral cortex produced ALZ-50 immunoreactivity in the 
cortex seven days later. Since ALZ-50 recognizes the 
phosphorylated form of tau, there may be an association 
between ~-amyloid and tau which is found in tangles. 
Interestingly, although this model produces amyloidal 
plaques and cell loss, it does not demonstrate changes in 
cholinergic neuronal functioning. 
Current Treatment for SPAT 
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The unknown etiology of SDAT has hampered efforts to 
devise an effective treatment for this disease. The lack of 
understanding as to the origin of the disease has promoted 
treatment strategies which are designed to address the 
various symptoms of the disease. 
The current therapy strategy is based on the assumption 
that the cholinergic deficit seen in the brains of SPAT 
patients is responsible for the cognitive and memory 
impairments. As discussed previously in this dissertation, 
the cholinergic system is linked intricately with 
neurochemical and behavioral changes seen in SPAT patients. 
Further, memory deficits can be induced in normal volunteers 
by administering a muscarinic receptor antagonist (Prachman 
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and Leavitt 1974). Therefore, many of the therapies have 
been aimed at providing the basal forebrain with additional 
ACh. This has been attempted through the use of ACh 
precursors (choline or lecithin) and AChE inhibitors such 
as: physostigmine, tetrahydroaminoacridine (tacrine), or 
huperzine (Hanin 1993). Further, therapy with muscarinic 
agonists such as bethanechol, AF102B, and arecoline has also 
been used in attempts to treat patients (Hanin 1993; Kan 
1992). Of these treatments, the use of AChE inhibitors has 
produced some moderate benefits, but unfortunately, they may 
also produce liver toxicity (Kan 1992; Cordell 1994). 
Several lines of evidence indicate that NTFs may be 
useful as therapeutic agents in the treatment of SDAT. NGF 
and BDNF are highly localized to the basal forebrain region 
(Phillips et al. 1991; Senut et al. 1990) where most of the 
cell loss occurs in SDAT patients. In addition to NTFs being 
located in the basal f orebrain, receptors for NGF are also 
found in this region in both normal and SDAT patients (Hefti 
1989; Strada et al. 1992; Kordower et al. 1989). Further, 
these NTFs have been shown to act on cholinergic neurons of 
this brain region and NGF has been specifically shown to 
produce changes in the neurochemical function of these 
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neurons, prevent cell death and promote behavioral recovery. 
Work in animals with NGF has led to the limited use of 
NGF in SDAT patients. NGF was administered to a SDAT patient 
and produced improved responses on several neuroanatomical 
and behavioral parameters (Olson et al. 1992). Prior to 
treatment the subject had several typical symptoms of SDAT 
including decreased cortical nicotinic binding, decreased 
brain blood flow, and poor cognitive abilities. NGF infusion 
into the right lateral ventricle of this patient improved 
all of these measures (Olson et al. 1992). Unfortunately, 
these improvements were temporary and three months after NGF 
treatment was discontinued, the disease continued to 
progress with all of these measures decreasing to levels at 
or below those seen prior to NGF treatment (Olson et al. 
1992). Further, this treatment produced pain as a side 
effect. This work indicates that NTFs may be useful in the 
future as therapeutic agents in neurodegenerative diseases, 
but that more studies are still necessary before reaching 
such a desirable stage. 
AF64A 
AF64A has been proposed as a selective toxin for 
cholinergic neurons. The work with AF64A has been directed 
towards developing an in vivo model of cholinergic 
deficiency in the brain (Hanin 1994) . The development of a 
cholinodef icient animal model would be useful for testing 
proposed therapeutic agents which may stimulate the 
production of ACh in cholinergic neurons 
Neurochemical Effects of AF64A in the Brain 
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When administered into the brain, AF64A alters several 
cholinergic markers including ChAT, AChE, ACh, and HAChT. 
AF64A decreases all of these markers by approximately 50% in 
the hippocampus after AF64A treatment (Potter et al. 1989; 
El Tarner et al. 1992; Chrobak et al. 1988; Chrobak et al. 
1987; Ikegarni et al. 1989; Opello et al. 1993). AF64A 
administration also significantly reduces potassium induced 
release of ACh in hippocampal slices (Leventer et al. 1985). 
These changes in cholinergic markers occur as soon as two 
days after administration of AF64A and last up to 180 days 
(El Tamer et al. 1992). 
In contrast to the decrease in cholinergic enzyme 
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activity in the hippocampus, AF64A has been shown to 
transiently increase septal ChAT activity by 45%. This 
increase occurs two to seven days post AF64A administration 
and returns to control levels by 14 days (El Tamer et al. 
1992). In addition to the changes that occur in the enzyme 
activity in the septum there are also changes in the number 
of ChAT-IR cells which remain in this region. Twenty eight 
days after AF64A treatment, the number of ChAT-IR cells were 
reduced 31-51% (Lorens et al. 1990; Chrobak et al. 1988). 
This reduction occurred in a selective population of septal 
neurons. The intermediate group was the most sensitive to 
AF64A while the ventral neurons were insensitive. This 
decrease in ChAT-IR is attributed to a loss of neurons since 
there is also a loss of fluro-gold labeling of these neurons 
(Dong et al. 1992). 
Cholinergic neurons in the striatum may also be 
sensitive to AF64A treatment depending on the dose and route 
of toxin administration. Rats treated by i.c.v. injection 
with AF64A (1-5 nmol) showed no change in ChAT or AChE 
activity (Moos et al. 1991; Leventer et al. 1985), HAChT, 
mACh receptor binding (Leventer et al. 1985) or ACh levels 
(Hortnagl 1987a; Chrobak et al 1987; Chrobak et al. 1988, 
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Opello et al. 1993; Potter et al. 1989) in the striatum. On 
the other hand, at very high doses (65 nmol), i.c.v. 
administration of AF64A produced a reduction in ACh, HAChT 
and ChAT activity (Fisher et al 1982) in the striatum of 
mice. The decrease in cholinergic markers in the striatum 
after i.c.v. administration of a high dose of AF64A (65 
nmol) is transient with recovery by day 21. In addition, if 
AF64A (0.1-10 nmol) is administered directly into the 
striatum there is a loss of AChE staining, ChAT activity, 
HAChT and ACh (McGurk et al. 1987; Sandberg et al. 1983). 
These decreases in the cholinergic markers in the striatum 
after AF64A occur in a dose dependent manner (McGurk et al. 
1987). 
Effect on Non-Cholinergic Neurons 
Although AF64A has clearly been shown to reduce 
cholinergic phenotypic markers in the SHP when administered 
by i.c.v. injection, other neurotransmitter systems can also 
be affected, in a secondary and transient manner. AF64A 
administration reduces markers for the serotonergic and 
noradrenergic systems. Serotonin (5-HT) and its metabolite, 
5-hydroxy-indole acetic acid (5-HIAA), are reduced in the 
hippocampus after i.c.v. AF64A (2-5 nmol) administration 
(Hortnagl 1987b). In addition to 5-HT, AF64A also reduces 
norepinephrine (NE) (Hortnagl et al. 1987a; Potter et al. 
1989) and glutamate levels (Hortnagl et al. 1991) in the 
hippocampus. 
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The effects of AF64A on non-cholinergic neurons are 
dose dependent. Changes in non-cholinergic markers are 
transient (Hortnagl et al. 1987a,b; Chrobak et al. 1988) 
compared with those that occur for up to 180 days in chol-
inergic neurons (El Tamer et al. 1992). These short term 
changes in the serotonergic and noradrenergic systems are 
occur secondary to changes in cholinergic neurons. Evidence 
for this is provided by the observations that hemicholinium-
3 (HC-3) or its analog, A4, block the changes that occur in 
both the cholinergic system as well as other neurotrans-
mitter systems (Potter et al. 1989). Stimulation of muscar-
inic receptors by pilocarpine prevents the decrease of 
glutamate in the hippocampus that occurs after AF64A 
treatment (Hortnagl 1991). Further, the changes in 5-HT are 
highly correlated with changes that occur in the cholinergic 
terminals in the hippocampus (H6rtnagl et al. 1987a). 
AF64A administration does not change the level of other 
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neurotransmitter systems in the hippocampus or septum. The 
dopaminergic system is not affected by AF64A administration. 
The levels of dopamine (DA) are neither reduced nor 
increased in the hippocampus of rats treated with AF64A 
(Hortnagl 1987a). In the septum, parvalbumin levels, 
indicative of GABAergic neurons, are not changed by i.c.v. 
AF64A administration (Dong et al. 1994). 
In the striatum, as in the hippocarnpus, i.c.v. AF64A 
reduces 5-HT levels in a transient manner (Hortnagl et al. 
1987a,b). When AF64A (8 nmol) was administered directly into 
the striatum, GAD and tyrosine hydroxylase activity were not 
reduced significantly (Sandberg et al. 1984). In contrast, a 
higher dose of AF64A (12 nmol) produced deficits in GAD and 
TH activity in the striatum. 
Changes in non-cholinergic striatal neurons are dose 
dependent requiring long term administration of high doses 
of AF64A. Additionally, some of these changes may be due to 
the non-specific tissue damage, such as neuritic cavitation, 
that is produced when very high doses of AF64A are injected 
directly into the tissue (McGurk et al. 1987). 
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Effects on Behavior and Memory 
In addition to its action on cholinergic neurons, AF64A 
alters the behavior of rats, causing them to become 
hyperactive, jumpy and more aggressive than controls 
(Ikegami et al. 1991; Leventer et al. 1985). 
Rats treated with AF64A by i.c.v. injection perform 
poorly on behavioral tests compared with controls. In the 
Morris water maze task, rats treated with AF64A by i.c.v. 
injection had a greater latency time in finding the 
platform, took a longer path to the platform, and spent less 
time in the target area (platform) (Opello et al. 1993; 
Armstrong et al. 1991). These difficulties indicate a 
deficit in spatial memory. AF64A has also been shown to 
impair the working memory of rats. AF64A injected rats 
perform more poorly than controls on behavioral tasks such 
as the T-maze and eight arm radial maze (Chrobak et al. 
1987; Chrobak et al. 1988). These deficits in memory, as 
determined by behavioral tests, indicate that AF64A induces 
both changes in cholinergic markers and memory. 
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Structure and Toxicity 
AF64A is structurally similar to choline (fig. 1) 
with the exception that two methyl groups on the nitrogen 
are cyclized into an aziridinium ring and a methyl group is 
extended into an ethyl group. This similarity in structure 
is believed to allow AF64A to act at the HAChT site on the 
terminals of cholinergic neurons. The effects of AF64A on 
cholinergic neurons are thought to be brought about by its 
action on the presynaptic terminals of these neurons since 
i.c.v. administration reduces cholinergic presynaptic 
markers (ChAT, HAChT and ACh) but not post synaptic markers 
such as muscarinic receptors (Fisher et al. 1982) in the 
hippocampus. Further, its toxic effects can be prevented by 
pretreatment with choline (Fisher et al. 1982) or HC-3 
(Potter et al. 1989) which compete with AF64A for uptake 
into the neuron via the HAChT route. 
Although AF64A's structural similarity to choline 
allows it to be selective for cholinergic neurons, the 
differences between their structures impart the necessary 
component to induce toxicity to the neurons (Hanin 1990) . 
CH3 
I+ 
HOCH2CH2N- CH3 
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Fig. 1. Comparison of the chemical structures of choline and 
AF64A. 
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The aziridinium ring which is formed during the synthesis of 
AF64A from its precursor AF64 (acetylethyl choline mustard 
hydrochloride) appears to be the structural component that 
produces AF64A's toxic effect. In vitro experiments 
comparing AF64A with either its precursor (AF64) or products 
without the aziridinium ring, indicate that these were three 
times less effective than AF64A in inhibiting HAChT in 
hippocampal synaptosomes (Hortnagl et al. 1988). This 
corresponds to the action of AF64A in vivo where AF64A 
reduced ACh content in the hippocampus by 68% while the 
precursor or products without the aziridinium ring only 
produced a 28-41% reduction (probably after partial 
formation of the aziridinium ring in vivo) (Hortnagl et al. 
1988). 
Recovery from AF64A 
Although AF64A produces deficits in cholinergic markers 
when administered in vivo, some of these deficits are 
reversible. Administration of AF64A (3 nmol/lateral 
ventricle) produced long term decreases in ChAT and AChE 
activity as well as HAChT in the hippocampus. These 
decreases lasted up to 180 days before their levels returned 
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to control (El Tamer et al.1992). The ability of cholinergic 
markers to recover is dose dependent (0.5 - 1.5 nmol/ 
ventricle) since rats treated with lower doses had their 
cholinergic markers return to control levels earlier than 
those treated at higher doses. Recovery of AF64A-induced 
cholinergic deficits (decrease in hippocampal ChAT) also 
occurred in newborn rats injected post-natal day two, whose 
ChAT levels returned to control after 58 postnatal days 
(Armstrong and Pappas 1991). 
In addition to spontaneous recovery, recovery of 
cholinergic markers, as well as behavioral measures, can 
also be induced by transplantation of basal forebrain 
tissue. Rats transplanted with either septal or nbM fetal 
tissue after AF64A treatment showed less reduction in 
cholinergic markers (HAChT, AChE staining, and ChAT 
activity) than AF64A treated rats which did not receive such 
transplants (Ikegami et al. 1989; Ikegami et al. 1991; 
Emerich et al. 1992). Further, in rats treated with AF64A 
and then receiving fetal transplants, there was an 
improvement in the performance on behavioral tasks (open 
field activity and radial arm maze) in comparison with rats 
only treated with AF64A (Ikegami et al. 1989; Ikegami et al. 
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1991; Emerich et al. 1992). 
Various chemical substances have also been used in 
attempts to reverse the action of AF64A on cholinergic 
neurons. In vitro AF64A reduces ChAT activity in rat brain 
aggregates. If NGF is administered after a two day delay, 
ChAT activity returns to control levels (Atterwill and 
Meakin 1990). In vivo, vitamin E, bFGF, NGF, ganglioside 
GMl, transforming growth factor a (TGF a) and epidermal 
growth factor (EGF) have been used in an attempt to produce 
recovery of AF64A decreases in cholinergic markers in the 
SHP. AF64A induced behavioral deficits, as well as the 
reduction in hippocampal ChAT and HAChT activity, were 
reversed by vitamin E (Wortwein et al. 1994; Johnson et al. 
1988) . In addition, bFGF has also been shown to reverse 
AF64A induced decreases in hippocampal ChAT activity (Potter 
and Morrison 1991). In contrast, neither NGF, TGF a, GMl or 
EGF reversed the AF64A induced decrease in hippocampal 
cholinergic markers (Johnson et al. 1988; Potter and 
Morrison 1991) . 
CHAPTER III 
BASIC FIBROBLAST GROWTH FACTOR IN AF64A TREATED RATS FAILS 
TO INCREASE CHOLINERGIC ENZYME ACTIVITY IN THE SEPTO-
HIPPOCAMPAL PATHWAY 
Summary 
Previous in vitro and in vivo work indicates that bFGF 
may play a role in the regulation of cholinergic neurons and 
their phenotypic markers. In the present study, i.c.v. 
administration of bFGF to AP64A treated rats did not produce 
any changes in ChAT or AChE activity in the hippocampus. In 
AF64A/bFGF (0.006 nmol) treated rats, septal ChAT activity 
remained unchanged while AChE activity decreased 34% 
compared with AF64A/CC treated rats. In addition, AF64A/bFGF 
treated rats had normal weight gain over the 14 days of 
treatment. This weight gain was comparable with that seen in 
the control (AF64A/CC) rats. These data indicate that bFGF 
has limited influence on cholinergic enzyme activity in the 
SHP of AF64A treated rats. 
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Introduction 
Basic fibroblast growth factor is a mitogen with a 
widespread distribution in the brain. Basic fibroblast 
growth factor like-IR has been localized to the cortex, 
caudate-putamen, hypothalamus, septum (medial and lateral) 
and hippocampus (dentate gyrus, CA2 and subiculum 
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regions) (Matsuyama et al. 1992). Basic fibroblast growth 
factor is thought to be produced locally since its mRNA is 
also found in these regions (hypothalamus, cortex, 
hippocampus, septum and striatum) (Powell et al. 1991; 
Ernfors et al. 1990b). The bFGF receptor, which is necessary 
for the action of bFGF, is also located in the cerebral 
cortex, hippocampus, cerebellum and brain stem. Surpris-
ingly, the bFGF receptor is not found in the septum or 
striatum (Wanaka, Johnson, and Milbrandt 1990). Several of 
these regions (particularly the septum and hippocampus) with 
high levels of bFGF mRNA and immuno-reactivity also have a 
large number of cholinergic neurons. This may indicate that 
bFGF plays a role in the survival of cholinergic neurons. 
In vitro, bFGF administration produced an increase in 
the survival of cholinergic basal forebrain cells. 
Administration of bFGF to septal cell cultures increases 
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ChAT-IR (Knusel et al. 1990) and ChAT activity (Yokoyama et 
al. 1994; Knusel et al. 1990). The action of bFGFs on ChAT 
activity in septal cultures is specific since it can be 
blocked by a bFGF antibody but, not an NGF antibody (Knusel 
et al. 1990). Basic fibroblast growth factor also increased 
cell proliferation (Knusel et al. 1990) and the number of 
AChE positive cells (Kushima et al. 1992) in septal 
cultures. 
When administered in vivo, bFGF appears to have a role 
in recovery from neuronal damage. Administration of bFGF 
(8.0 µg) partially attenuated the loss of ChAT-IR that 
occurred in the MS after the FF was transected (Otto, 
Frotscher, and Unsicker 1989). This effect is similar to, 
but not as large as, those seen with NGF (Otto, Frotscher, 
and Unsicker 1989). In vivo bFGF (0.084 µg) administration 
can reduce the loss of AChE staining in the MS/DBC that 
occurs after the FF is transected (Anderson et al. 1988). 
The loss of hippocampal ChAT activity due to partial FF 
transection can be partially prevented by injection of 0.02-
0.01 µg bFGF into the lateral ventricle (Barotte et al. 
1989; Araujo, Lapchak, and Hefti 1993). 
In the brain, bFGF also appears to be protective 
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against chemical insults. The loss of striatal dopamine 
after MPTP treatment is partially reversed by bFGF 
administration (Otto and Unsicker 1990) . In addition, bFGF 
has been shown to protect against the toxic effects of the 
cholinotoxin, AF64A (Potter and Morrison 1991) . Administra-
tion of AF64A into the lateral ventricles produces a 
decrease in cholinergic phenotypic markers in the 
hippocampus (El Tamer et al. 1992; Leventer et al., 1985; 
Potter and Morrison 1991) . These reductions in cholinergic 
markers can be attenuated by i.c.v. administration of 
0.084 µg bFGF (Potter and Morrison 1991). 
The current study focuses on the effect of in vivo 
administration of bFGF on cholinergic neurons in the SHP of 
AF64A treated rats. Basic fibroblast growth factor admin-
istration did not stimulate cholinergic enzyme activity in 
the hippocampus or septum of AF64A treated rats. Basic 
fibroblast growth factors lack of action on cholinergic 
enzyme activity in the SHP is in contrast to the actions of 
other growth factors such as NGF or BDNF. 
Materials and Methods 
Animals 
Adult, male Sprague-Dawley rats (Zivic Miller 
Laboratories, Allison Park, PA.) weighing between 
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188-324 grams were used for this study. They were housed two 
per cage in a room on a 12 hour light cycle and had access 
to food and water ad libitum. A total of 24 rats were used 
in this study. The rats were weighed at the time of surgery, 
on day 7, and on day 14. These rats were used under the 
auspices of the IACUC. 
AF64A 
AF64A was prepared according a standard procedure 
(Fisher et al. 1982). Briefly, acetylethylcholine mustard 
hydrochloride (UCB, Belgium) was dissolved in water to a 
concentration of 0.667 mM. This solution was adjusted to pH 
11.5 with sodium hydroxide (NaOH; 1M-6M) and stirred for 20 
minutes at room temperature. The solution was then adjusted 
to pH 7.3 with hydrochloric acid (HCl; 1M-6M) and stirred at 
room temperature for one hour. This solution was prepared 
fresh before each experiment and kept on ice. Preparation of 
AF64A in this manner produces 85-90% cyclization of the 
56 
aziridinium ring (Gill and Rang l966; El Tamer et al. 1992). 
surgical Procedures and Drug Treatment 
The rats were anesthetized with equitensin (3ml/kg) 
intraperitoneal injection, placed into a stereotaxic 
apparatus (Kopf) and their skull was exposed. 
AF64A (1 nmol/1.5 ~l) was injected bilaterally, one 
side at a time, into the lateral ventricles at a rate of 
0.5 µl per minute. These injections were made at the 
coordinates: -0.8 mm posterior, +/- l.5 mm lateral, and -3.6 
mm ventral to bregma (Paxinos and Watson, 1986) . A sterile 
cannula-osmotic pump assembly (Alza, Palo Alto, CA), filled 
with either cytochrome C (CC; a control protein) or bFGF 
(Harlan Bioproducts, Indianapolis, IN) dissolved in 
artificial cerebrospinal fluid (NaCl, 123 mM; CaC1 2 , 0.86 
mM; KCl, 3.0 mM; MgC12 , 0.89 mM; NaHC03 , 25 mM; NaH2 P04 , 0.5 
mM and Na2HP04 , 0.25 mM), was pre-equilibrated for at least 
3 hours in sterile saline at 37° C. The osmotic pump was 
implanted subcutaneously on the animal's back and the tip of 
the cannula was stereotaxically lowered -4.0 mm ventral from 
bregma into either the right or left lateral ventricle. The 
cannula was affixed to the skull, via an anchoring screw, 
with dental cement (Coralite Dental Products, Skokie, Il) . 
The wound was closed and the rats were administered 0.3 ml 
(SO mg/ml) ampicillin subcutaneously. 
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AF64A treated rats received either a total of 3.24 nmol 
cc (equivalent to 40 µg and the same dose used in the other 
NTF experiments) or either 0.006 or 0.011 nmol (equivalent 
to 0.1 and 0.2 µg) bFGF. These doses of bFGF were chosen 
because in this range, bFGF is effective in stimulating ChAT 
activity and AChE staining (Potter and Morrison 1991; 
Anderson et al. 1988; Araujo, Lapchak and Hefti 1993). 
Cytochrome C or bFGF were administered continuously for 14 
days. At the end of the treatment the rats were sacrificed 
by decapitation and the brains were dissected on ice. The 
hippocampus and septum were immediately placed on dry ice 
and subsequently stored at -70°C. 
Enzyme Assay 
Tissue preparation 
The hippocampus and septum were thawed in ice cold 
sodium phosphate buffer 75 mM, pH 7.4, (1 ml for hippocampal 
tissue and 0.6 ml for septal tissue) and homogenized (20 
sec., setting 5 on a Polytron homogenizer model# PT 10/35). 
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ChAT activity 
The ChAT assay followed the Fonnum method (1975). In 
brief, 10 µl of tissue homogenate was added to 10 µl of 
buffer substrate [cold sodium phosphate, 75 mM pH 7.4; NaCl, 
600 mM; MgCl 2 , 40 mM; eserine, 2.0 mM; bovine serum albumin, 
0.05%; choline-iodide, 10 rnM; and [3H]acetyl coenzyme A, 
0.87 mM (~ 20 mCi/mmol)]. This mixture was then incubated 
for 30 minutes at 37°C and the tubes placed on crushed ice 
following incubation. One hundred and fifty µl of sodium 
tetraphenylboron solution (75 mg/ml in 3-heptanone) was 
added to each tube and the tubes were vortexed and 
centrifuged. After centrifugation, 100 µl of the organic 
(top) layer was removed and placed into scintillation vials. 
Ten ml of scintillation cocktail was added and the vials 
were counted using liquid scintillation spectrometry. The 
level of ChAT activity was measured by subtracting the 
disintegrations per minute (dpm) in the blank tubes (without 
tissue) from the dpm in the tubes with tissue. 
AChE activity 
The AChE assay is similar to the ChAT assay but with 
the following modifications (Leventer et al. 1985). Tissue 
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homogenate (10 µl) was added to 20 µl of buffer substrate 
[cold sodium phosphate buffer, 75mM, pH 7.0; AChI, lOmM and 
[ 3H]ACh iodide 10 mM (~ 8 mCi/mmol)]. This mixture was 
incubated for 20 minutes at 37°C and the tubes were then 
placed into crushed ice. Ice cold water (30 µl) was then 
added to each tube followed by 150 µl sodium tetraphenyl-
boron solution (75 mg/ml in 3-heptanone) . The tubes were 
then vortexed, centrifuged, and frozen for 30 minutes at 
-20°C. When removed from the freezer the organic (top) layer 
was discarded and the aqueous (bottom) layer thawed. Thirty 
µl of this aqueous layer was placed into scint-illation 
vials and 10 ml of scintillation cocktail was added. These 
vials, along with blank tubes (assay without tissue 
substrate), were counted using a liquid scintillation 
spectrometer. The level of AChE activity was calculated by 
subtracting the dpm in the blank tubes from the dpm in the 
assay tubes with tissue. 
Protein Determination 
Tissue protein levels were assessed by the method of 
Lowry et al. (1951) for both the ChAT and AChE assays. 
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Statistical Analysis 
The levels of enzyme activity in the rats are 
expressed as either nmol/mg/hr or ~ of rat treated with 
AF64A/CC control. The values indicated are means ± SEM. The 
data were analyzed by 'ANOVA followed by post-hoc analysis 
(Fisher LSD) . The changes in the weight of the rats are 
expressed as the % mean ± SEM of the rats' initial weight. 
The weight data were analyzed by repeated measures ANOVA. 
Results 
In the hippocampus, there was no significant difference 
in ChAT activity between the treatment groups (f=l.85, 
p=0.181, df=2). Neither dose of bFGP 0.006 and 0.011 nmol 
produced any significant change in hippocampal ChAT activity 
compared with AF64A/CC treated rats (fig. 2). Septal ChAT 
activity was not changed by treatment with either AF64A/CC 
or AF64A/bFGF (f=2.70, p=0.0.091, df =2) (fig. 2). 
Treatment with either dose of bFGF (0.006 and 0.011 
nmol) after AF64A treatment did not alter hippocampal AChE 
activity (f=l.452, p=0.258, df=2) (fig. 3). In the septum 
there was a significant difference between the treatment 
groups (f=5.72, p=0.010, df =2). The AF64A/bFGF (0.006 nmol) 
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Fig. 2. ChAT activity was determined in the SHP of rats 
treated with an i.c.v. injection of AF64A (1 nmol/ventricle) 
and then continuously infusea with either 0.006 or 0.011 
nmol bFGF for 14 days. The aata represent the mean ± SEM for 
8 rats per group. 
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Fig. 3. AChE activity was determined in the SHP of rats 
treated with an i.c.v. injection of AF64A (1 nmol/ventricle) 
and then continuously infused with either 0.006 or 0.011 
nmol bFGF for 14 days. There were 8 rats per groups. The 
data represent the mean± SEM for 8 rats per group. *, 
p< 0.05 compared with the AF64A/CC and AF64A/bFGF 0.011 nmol 
treated rats. 
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The AF64A/bFGF (0.006 nmol) treated rats showed significant 
(p=0.011) reduction in septal AChE compared with AF64A/CC 
treated rats. AChE activity in the septum of AF64A/bFGF 
(0.011 nmol) treated rats remained unchanged (fig. 3). 
Rats in all treatment groups gained weight over the 14 
day treatment period and there was no significant difference 
between treatment groups (f=J.00, p=0.071, df=3). The 
AF64A/CC, AF64A/bFGF (0.006 nmol) and AF64A/bFGF (0.011 
nmol) treated rats all increased their weight in a similar 
manner (28-50% increase from their initial weight) (table 1). 
Discussion 
In the present work, bFGF administration to AF64A 
treated rats did not increase either hippocampal or septal 
ChAT activity. This is in contrast with other work which has 
shown that bFGF stimulates recovery of cholinergic markers 
in the SHP. Studies in which cholinergic cell loss occurs 
after FF transection have shown that bFGF increases 
hippocampal ChAT activity (Araujo, Lapchak and Hefti 1993). 
Table 1.-- bFGF does not attenuate weight gain in AF64A 
treated rats. 
TREATMENT WEIGHT-DAY 7 WEIGHT-DAY 14 
AF64A/CC 110 (3.13) 132 (3.21) 
AF64A/bFGF ( 0. 1) 120 (1.61) 150 (2.90) 
AF64A/bFGF ( 0. 2) 113 (3.49) 128 (3.89) 
Data are represented as the mean ± SEM of the % of the 
rats' initial weight. 
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rn rats with these lesions, bFGF administration increased 
the number of septal AChE (Anderson et al. 1988) and ChAT 
positive cells (Otto, Frotscher and Unsicker 1989; Araujo, 
Lapchak and Hefti 1993). 
Previous work with AF64A and bFGF has shown that bFGF 
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produces a 30% recovery in ChAT activity in the hippocampus 
of AF64A treated rats (Potter and Morrison 1991) . Consistent 
with the present work, Potter and Morrison (1991) also 
showed that bFGF did not produce any change in the septal 
ChAT activity in AF64A treated rats (Potter and Morrison 
1991). 
The lack of effect in the present study cannot be 
accounted for by the use of an inappropriate dose of bFGF. A 
dose of 0.084 µg bFGF, administered over 14 days, is 
effective in stimulating cholinergic enzyme activity in 
AF64A treated rats (Potter and Morrison 1991) . Other work 
has shown that 0.01 µg bFGF, injected twice a week over 21 
days (0.105 µg total), increased hippocampal ChAT activity 
(Araujo, Lapchak and Hefti 1993) . In addition, Anderson et 
al. (1988) found that 0.084 ~g, administered over 14 days, 
reversed the loss of AChE staining in the septum after FF 
transection. These studies indicate that the doses of bFGF 
used in the current work should have been appropriate to 
alter both ChAT and AChE activity in AF64A treated rats. 
66 
In the present study, all of the animals had normal 
weight gain over the 14 day treatment period and these 
weight gains were comparable across treatment groups. This 
is in contrast to previous work which has shown that rats 
treated with bFGF after FF transection had an attenuated 
weight gain over 21 days of treatment (Araujo, Lapchak and 
Hefti 1993). Further, the increased weight gain in the 
present study differs from the effect of other NTFs on 
weight gain (Lapchak and Hefti, 1992; Williams 1991b; 
Williams and Oostveen 1992). The data in the present study 
indicate that, in AF64A treated rats, bFGF may not act like 
other NTFs (see chapters 4, 5 and 6) . 
A lack of growth factor infusion may have contributed 
to the results of the present study. Although all of the 
osmotic pumps were checked after the rats were sacrificed 
and found to be empty, it is possible that since bFGF is a 
larger protein than either NGF or BDNF (MW 17,500, 13,000 
and 12,500 respectively) the bFGF protein adhered to the 
wall of the pump and only the artificial cerebral spinal 
fluid solution was pumped out. 
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The lower dose of AF64A (1 nmol/ventricle) used in the 
present study also may have played a role in the results. 
This dose of AF64A in the AF64A/CC treated rats produced a 
level of hippocampal enzyme activity of 33 nmol/mg/hour for 
ChAT activity and 1875 nmol/rng/hour for AChE activity. These 
levels of activity are similar to those normally found in 
vehicle (water at pH 7.3) treated rats (35-42 nmol/mg/hr for 
ChAT and 2000-2300 nmol/mg/hour for AChE) . Fimbria fornix 
transections or treatment with 2 nmol AF64A produce 
decreases in hippocampal ChAT activity of 50%-60% (Potter 
and Morrison 1991; Araujo, Lapchak and Hefti 1993). A larger 
change in cholinergic enzyme activity than in the present 
study may be necessary for bFGF to affect cholinergic 
neurons in the SHP. Whether bFGF acts on normal, non-
lesioned, cholinergic neurons is unknown. 
In conclusion, the present work found that bFGF did not 
stimulate cholinergic enzyme activity in the SHP of AF64A 
treated rats. Results of the current study indicate that a 
higher dose of AF64A should be used for subsequent studies. 
The lack of effect of bFGF on cholinergic neurons of the SHP 
suggests that further work with this NTF in AF64A treated 
rats would not be beneficial in increasing our understanding 
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of the action of exogenous administration of this NTF. 
CHAPTER IV 
EFFECT OF NERVE GROWTH FACTOR IN NORMAL AND ETHYLCHOLINE 
MUSTARD AZIRIDINIUM (AF64A) TREATED RATS: SENSITIZATION OF 
CHOLINERGIC ENZYME ACTIVITY IN THE SEPTO-HIPPOC.AMPAL PATHWAY 
Summary 
This study examined the effects of nerve growth factor 
(NGF) administration on cholinergic enzyme activity in both 
normal and AF64A treated rats. Choline acetyltransferase 
(ChAT) and acetylcholinesterase (AChE) activity were 
measured in the hippocampus and septum of rats chronically 
administered NGF (0.38-3.08 nmol) into the lateral 
ventricles for 14 days. In both normal and AF64A treated 
rats, NGF increased cholinergic enzyme activity in a dose-
dependent manner. NGF increased ChAT activity in normal rats 
by 149% but, a greater effect was observed in AF64A treated 
rats that had a 273% of control increase in activity. NGF 
increased AChE activity in normal rats by 135% but produced 
a 221% increase in this activity in AF64A-treated rats. 
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Introduction 
NGF is a protein involved in the development and 
maintenance of neurons in both the peripheral nervous system 
(PNS) and the central nervous system (CNS) (for reviews see 
Levi-Montalcini 1987; Varon et al. 1988; Korsching, 1993). 
NGF acts on sympathetic and sensory neurons of the PNS as 
well as on cholinergic neurons of the basal f orebrain in the 
CNS (Longo et al. 1993; Ayer-Lelievre 1983; Varon et al., 
1989) . In the basal forebrain, NGF mRNA and NGF receptors 
have been localized in the septo-hippocampal pathway (SHP) 
(Lindsay et al. 1994; Cuello, Maysinger, and Garofalo 1992; 
Lauterborn et al. 1994a; Senut et al. 1990). In this 
pathway, immunoreactivity for NGF and its receptors have 
been co-localized with neurons expressing cholinergic 
phenotypic markers (Woolf, Gould and Butcher 1989; Liberini 
and Cuello 1994; Rylett and Williams, 1994). This evidence 
and supporting data demonstrate the retrograde transport of 
NGF (Ferguson et al. 1991; Korsching 1986; Liberini and 
Cuello 1994) and have established NGF as a key neurotrophic 
factor in the SHP. 
Transection of the PF, the major septal cholinergic 
pathway to the hippocampus (Amaral and Kurz 1985), causes a 
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reduction in cholinergic phenotypic markers such as ChAT 
immunoreactivity, AChE staining and ChAT activity in the SHP 
(Armstrong et al. 1987; Tuszynski et al. 1990). In vivo 
administration of NGF has been shown to reverse cholinergic 
deficits found after FF transection (Gage et al. 1988; Hagg 
et al. 1988; Hagg et al. 1989; Kromer 1987; Montero and 
Hefti 1988; Svendsen, Cooper and Sofroniew 1991). 
Although work in rats with FF transections indicate 
that NGF treatment can produce changes in cholinergic 
markers, studies assessing the action of NGF in normal, 
unablated rats have not been as clear. Several studies have 
indicated that the effect of NGF on cholinergic markers in 
the SHP is dependent on damage or cholinergic deficiencies 
in this pathway (Gage et al. 1988; Hefti et al. 1984; 
Schinstine and Cornbrooks 1989; Williams, Jodelis and Donald 
1989; Garofalo, Ribeiro-Da-Silva and Cuello 1992). Other 
studies indicate that NGF administration to rats with an 
intact SHP can increase cholinergic phenotypic markers in 
the medial septum and hippocampus (Fusco et al. 1989; 
Vantini et al. 1988). 
A direct comparison between the effects of NGF on 
septal cholinergic neurons in normal rats and rats with 
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decreased cholinergic phenotypic markers has not been done. 
Further, much of the work involving NGF administration in FF 
transected rats has focused on the effects seen at the cell 
bodies located in the medial septum. A more complete 
analysis of the action of NGF on the entire SHP (the cell 
body and terminal region) is necessary in order to determine 
the interaction of these two regions when rats with and 
without reduced cholinergic phenotypic markers are treated 
with NGF. 
AF64A is a neurotoxin which has been previously shown 
to be selective in a dose-dependent manner for cholinergic 
neurons in the SHP (Chrobak et al. 1988; Fisher et al. 1982; 
Hortnagl et al. 1987a,b). When administered into the lateral 
ventricle AF64A reduces ChAT and AChE activity in the 
hippocampus (Chrobak et al. 1987; Calhoun et al. 1986; El 
Tamer et al. 1992; Hanin 1990) as well as high affinity 
choline transport (HAChT), acetylcholine (ACh), and ChAT 
immune-reactivity in the SHP (El Tamer et al. 1992; Fisher 
et al. 1982; Leventer et al. 1985; Lorens et al. 1991). 
Accordingly, AF64A provides a means to produce cholinergic 
deficits in the SHP without the gross anatomical disruption 
seen when the FF is transected. 
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The present study compared the effects of NGF 
administration on SHP neurons in AF64A-treated rats with its 
effects on normal, non-AF64A treated rats. Whether AF64A 
treated rats were more sensitive to chronic treatment with 
NGF and whether this sensitivity was dose dependent was 
evaluated. NGF was found to increase cholinergic enzyme 
activity in the SHP of both the AF64A treated and non-
treated rats, in a dose dependent manner. Further, AF64A 
treated rats were more sensitive to the effects of NGF on 
cholinergic enzyme activity. 
Materials and Methods 
Animals 
Adult, male Sprague-Dawley rats (Zivic Miller 
Laboratories, Allison Park, PA.) weighing between 230-392 
grams were used. They were housed two per cage in a room on 
a 12 hour light cycle and had access to food and water g.d 
libitum. A total of 126 rats were used in this study. The 
rats were weighed at the time of surgery as well as 7 and 14 
days post surgery. These rats were used under the auspices 
of the IACUC. 
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AF64A 
AF64A was prepared according to standard methods 
(Fisher et al. 1982). Briefly, acetyl ethylcholine mustard 
hydrochloride (UCB, Belgium) was dissolved in water to a 
concentration of 1 mM. This solution was adjusted to pH 11.5 
with sodium hydroxide (NaOH; 1M-6M) and stirred for 20 
minutes at room temperature. The solution was adjusted to pH 
7.3 with hydrochloric acid (HCl; lM-6M) and stirred at room 
temperature for one hour. This solution was prepared fresh 
before each experiment and kept on ice. Preparation of AF64A 
in this manner produces 85-90% cyclization of the 
aziridinium ring (Gill and Rang 1966; El Tamer et al. 1992). 
Surgical Procedures and Drug Treatment 
Rats were anesthetized with intraperitoneal injections 
of equitensin (3ml/kg), placed into a stereotaxic apparatus 
(Kopf) and their skull was exposed. 
In the NGF dose-response experiment in normal rats, the 
rats were sham operated by having two needles (26 gauge) 
lowered into the lateral ventricles through two holes 
drilled at the coordinates of: -0.8 mm posterior, +/- 1.5 mm 
lateral, and -4.0 mm ventral to bregma (Paxinos and Watson 
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1986) . The needles were left in place for one minute and 
then removed. A sterile cannula-osmotic pump assembly (Alza, 
Palo Alto, CA), filled with either cytochrome C (CC; a 
control protein) (40 µg; 3.24 nmol) or NGF (5-40 µg; 0.38-
3.08 nmol total) (Harlan Bioproducts, Indianapolis, IN) 
dissolved in artificial cerebrospinal fluid (NaCl, 123 mM; 
CaC1 2 , 0.86 mM; KCl, 3.0 mM; MgC1 2 , 0.89 mM; NaHC03 , 25 mM; 
NaH2 P04 , 0.5 mM and Na2HP04 , 0.25 mM) containing 1% bovine 
serum albumin was pre-equilibrated for at least three hours 
in sterile saline at 37°C. The osmotic pump was implanted 
subcutaneously on the animal's back and the tip of the 
cannula was stereotaxically lowered into either the right or 
left lateral ventricle. The cannula was affixed to the 
skull, via an anchoring screw, with dental cement (Coralite 
Dental Products, Skokie, Il). The wound was closed and the 
rats were administered 0.3 ml (50 mg/ml) ampicillin 
subcutaneously. One of the 40 rats in this experiment died 
prior to completion. 
In the dose-response experiments with AF64A treated 
rats, the control rats (VEH/CC) had water at pH 7.3 as 
vehicle (VEH) injected into the lateral ventricles (see 
coordinates given above) . Rats in the AF64A treatment groups 
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had AF64A (1.5 nmol) injected into their lateral 
ventricles. These injections were bilateral, one side 
injected at a time, at a rate of 0.5 µl per minute. The 
cannula-pump assembly was implanted as described for the 
normal rats. In this experiment 48 rats were used of which 3 
were eliminated due to surgical difficulties and one died. 
In both dose-response experiments, CC or NGF (5-40 µg; 
0.38-3.08 nmol total) was administered continuously for 14 
days. The doses of NGF were determined from previous work 
which has shown that administration of 16.8, 40 or 80 µg NGF 
to FF transected rats increases cholinergic phenotypic 
markers in the SHP (Hefti, Dravid and Hartikka 1984; Montero 
and Hefti 1988; Williams, Jodelis and Donald 1989). At the 
end of the treatment the rats were sacrificed by 
decapitation and the brains were dissected on ice. The 
tissue samples (hippocampus, septum and striatum) were 
immediately placed on dry ice and subsequently stored at -
70°c. 
In a third experiment directly comparing the effects of 
NGF in VEH and AF64A treated rats, either VEH (water, pH 
7.3) or AF64A (1.5 nmol) were administered bilaterally into 
the lateral ventricles. Post injection, the rats were 
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implanted with a cannula-pump assembly containing either 
cc or NGF (3.08 nmol) as described previously in this 
dissertation. Therefore, this experiment had four treatment 
groups: VEH/CC, AF64A/CC, AF64A/NGF and VEH/NGF. An 
additional group, which corresponded to the controls in the 
dose-response study in normal rats, was sham operated and 
then administered CC. The rats were treated for 14 days and 
then the hippocampus, septum, and striatum were collected. A 
total of 38 rats were used in this experiment (14 in the 
control group and six to eight in all other treatment 
groups). Of these 38 rats, one was eliminated from the 
analysis due to post-surgical complications and one rat died 
during the experiment. 
Enzyme Assays 
Tissue preparation 
All tissue samples (hippocampus, septum, and striatum) 
were thawed in ice cold sodium phosphate buffer 75 mM, pH 
7.4, (1 ml for hippocampal tissue, 0.6 ml for septal tissue 
and 2 ml for striatal tissue) and homogenized (20 sec. @ 
setting 5 on a Polytron homogenizer model # PT 10/35). For 
the septal and hippocampal samples, the tissue homogenate 
was then divided into two aliquots, one for the ChAT and 
AChE assays and the other for the GAD assay. The ChAT/AChE 
homogenate was frozen at -70°C until the assays were 
conducted. To the GAD homogenate, 0.1% Triton XlOO and 2.5 
mM aminoethylisothiouronium bromide in 100 mM potassium 
phosphate buffer (pH 7.2) was added. 
ChAT activity 
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The ChAT assay followed the Ponnum method (1975) . In 
brief, 10 µl of tissue homogenate was added to 10 µl of 
buffer substrate {cold sodium phosphate, 75 mM pH 7.4; NaCl, 
600 mM; MgC1 2 , 40 mM; eserine, 2.0 mM; bovine serum albumin, 
0.05%; choline iodide, 10 mM; and [3H]acetyl coenzyme A, 
0.87 mM (= 20 mCi/mmol)}. This mixture was then incubated 
for 30 minutes at 37°C and the tubes placed on crushed ice 
following incubation. One hundred and fifty µl of sodium 
tetraphenylboron solution (75 mg/ml in 3-heptanone) was 
added to each tube and the tubes were vortexed and 
centrifuged. After centrifugation, 100 µl of the organic 
(top) layer was removed and placed into scintillation vials. 
Ten ml of scintillation cocktail was added and the vials 
were counted using liquid scintillation spectrometry. The 
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level of ChAT activity was measured by subtracting the 
disintegrations per minute (dpm) in the blank tubes (without 
tissue) from the dpm in the tubes with tissue. 
AChE activity 
The AChE assay is similar to the ChAT assay, but with 
the following modifications (Leventer et al. 1985). Tissue 
homogenate (10 µl) was added to 20 µl of buffer substrate 
[cold sodium phosphate buffer, 75m.M, pH 7.0; AChI, lOmM and 
[ 3H]ACh iodide 10 mM (= 8 mCi/mmol)]. This mixture was 
incubated for 20 minutes at 37~c and the tubes were then 
placed into crushed ice. Ice cold water (30 µl) was then 
added to each tube followed by 150 µl sodium 
tetraphenylboron solution (75 mg/ml in 3-heptanone). The 
tubes were then vortexed, centrifuged, and frozen for 30 
minutes at -20°c. When removed from the freezer the organic 
(top) layer was discarded and the aqueous (bottom) layer 
thawed. Thirty µl of this aqueous layer was placed into 
scintillation vials and 10 ml of scintillation cocktail was 
added. These vials, along with blank tubes (assay without 
tissue substrate), were counted using a liquid scintillation 
spectrometer. The level of AChE activity was calculated by 
subtracting the dpm in the blank tubes from the dpm in the 
assay tubes with tissue. 
GAD activity 
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Glutamic acid decarboxylase activity was determined by 
( 3H]GABA formation and cation exchange isolation (Maderdrut 
1979). Twenty microliters of tissue homogenate was added to 
30 µl of buffer substrate containing: 500 µM EDTA tetra-
sodium salt hydrate, 200 ~M pyridoxal-5'-phosphate, 12 mM 
glutamic acid and 10 mM GABA in potassium phosphate buffer 
(pH 7.2, 100 mM). This solution was spiked with [3H] 
glutamic acid for a specific activity of 0.27 µCi per assay. 
The blanks, used to define non-specific activity, consisted 
of tubes containing 20 µl of buff er substituted for the 
tissue homogenate. The samples were incubated for 30 minutes 
at 37°C and then placed on ice while 500 µl of 5% trichlo-
roacetic acid was added before the tubes were vortexed. The 
samples were loaded into column containing 4 cm of 50W-X4 
cation exchange resin (Bio-Rad Laboratories, Melville, N.Y.) 
which had been equilibrated with 4 ml of 2N NaOH followed by 
5 ml of 0.2M citric acid. In order to remove any non-
specific bound [3H] glutamic acid, the columns were washed 
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with 9 ml of sodium citrate buffer (0.2M, pH 3.5) and then 
[ 3H] GABA was eluted by the addition of 4 ml of cold sodium 
acetate (0.2M, pH 5.5) to the column. The eluate was 
collected into scintillation vials and 12 ml of scintill-
ation cocktail was added. The vials were counted and the 
amount of specific activity was determined by subtracting 
the dpm in the blanks from those in the samples. 
Protein Determination 
Tissue protein levels were assessed by the method of 
Lowry et al. (1951) for both the ChAT and AChE assays. 
Statistical Analysis 
The level of enzyme activity in the rats are expressed 
as either nmol/mg/hr or % control. The values indicated are 
means ± SEM. The data were analyzed by ANOVA followed by 
post-hoc analysis (Fisher LSD) . Changes in the weight of the 
rats are expressed as the ~ mean ± SEM of the rats' initial 
weight and these data were analyzed by repeated measures 
ANOVA. 
Results 
Cholinergic Enzyme Activity in Normal Rats 
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In normal rats, 14 day administration of NGF changed 
cholinergic enzyme activity in both the hippocampal and 
septal regions. NGF produced a significant (f=6.99, p=0.000, 
df=4) increase in ChAT activity in the hippocampus (fig. 4). 
This increase was dose-dependent since the level of enzyme 
activity in rats treated with 3.08 nmol NGF was signif-
icantly greater (142% of control) than that in rats treated 
with 0.38 nmol NGF (130~ of control, p=0.017). The septal 
region also showed a significant increase in the level of 
ChAT activity (f=4.87, p=0.003, df=4) with the highest being 
149% of control for the dose of 3.08 nmol NGF (fig. 4). 
Hippocampal and septal AChE activity remained unchanged 
after NGF treatment (f=0.55, p=D.703, df=4 and f=0.87, 
p=0.491, df=4 respectively; fig. 5). 
GAD activity in the hippocampus remained unchanged by 
NGF treatment (f=0.91, p=0.472, df=4; fig. 6). In the 
septum, there was a significant alteration in GAD activity 
(f=2.93, p=0.035, df=4). This significance is attributed to 
changes in the level of GAD activity across the doses of NGF 
(p< 0.05, 0.38 nmol verses 0.77, 1.54 and 3.08 nmol NGF). 
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Fig. 4. ChAT activity in the hippocampus and septum of 
normal rats treated for 14 days with either CC (40 µg, 3.24 
nmol) or NGF (5-40 µg, 0.38-3.08 nmol). There were 7-8 rats 
per treatment group. ~, p< 0.05 compared with CC treated 
rats and a, p< 0.05 compared with 0.38 nmol NGF. 
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Fig. 5. AChE activity in the hippocampus and septum of 
normal rats treated for 14 days with either CC (40 µg, 3.24 
nmol) or NGF (5-40 µg, 0.38-3.08 nmol). There were 7-8 rats 
per treatment group. 
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Fig. 6. GAD activity in the BHP of normal rats treated with 
NGF (0.38-3.08 nmol) or CC (3.24 nmol) over a 14 day period. 
Each group consisted of 7-8 rats. a, P< 0.05 compared with 
NGF 0.38 nmol. 
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None of the NGF treated rats had levels of GAD activity 
significantly different (p >0.05) from rats treated with CC. 
In the striatal tissue, NGF produced an increase of 
both ChAT and AChE activity. ChAT activity in this tissue 
was significantly increased (f=l9.60, p=0.000, df=4). The 
doses of 0.38 and 3.08 nrnol NGF increased ChAT activity 123% 
and 170% of control respectively (fig. 7). AChE activity in 
the striatum was also significantly increased (f=3.41, 
p=0.019, df=4). This increase only occurred at the highest 
dose of NGF ( 3. 0 8 nmol) (fig. B) . The increase in both of 
these enzymes was dose-dependent since the highest dose of 
NGF (3.08 nmol) induced a larger increase in enzyme activity 
than the lowest dose (0. 38 nrnol) (p< 0. 05). 
Changes in Cholinergic Enzyme Activity in AF64A Treated Rats 
In the dose-response experiment with AF64A treated 
rats, hippocampal ChAT activity was unchanged (f=l.30, 
p=0.284, df=5). Rats treated with AF64A/CC had a 28%, non-
significant, reduction in ChAT activity from control values 
(fig. 9). AF64A/NGF treated rats did not have any changes in 
the level of hippocampal ChAT activity compared with control 
rats (fig. 9). 
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Fig. 7. ChAT activity in the striatum of normal rats 
treated for 14 days with either CC (40 µg, 3.24 nmol) or NGF 
(5-40 µg, 0.38-3.08 nmol). There were 7-8 rats per treatment 
group. *, p< 0.05 compared with CC treated rats and a, p< 
0.05 compared with 0.38 nmol NGF. 
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Fig. 8. AChE activity in the striaturn of normal rats treated 
for 14 days with either CC (40 µg, 3.24 nmol) or NGF (5-40 
µg, 0.38-3.08 nmol). There were 7-8 rats per treatment 
group. *, p< 0.05 compared with CC treated rats and a, 
P< 0.05 compared with 0.38 nmol. 
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Fig. 9. ChAT activity in the SHP of AF64A/NGF treated rats. 
VEH (water at pH 7.3) or AF64A (1.5 nmol/ventricle) was 
administered by i.c.v. injection. Rats were then infused 
with either CC (3.24 nmol) or NGF (0.38-3.08 nmol) 
continuously for 14 days. Each treatment group consisted of 
7-8 rats. *, p< 0.05 compared with VEH/CC treated rats; **, 
p< 0.05 compared with AF64A/CC treated rats and a, p< 0.05 
compared with AF64A/NGF 0.38 nmol. 
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AF64A/NGF treated rats showed a robust increase 
(f=l0.39, p=0.000, df=5) in septal ChAT activity at all 
doses of NGF administered. ChAT activity increased up to 
273% of control in rats administered 1.54 nmol of NGF. This 
increase was significantly (p=0.018) greater compared with 
rats administered 0.38 nmol NGF and indicates that NGF 
stimulation of ChAT activity in AF64A treated rats is dose-
dependent (fig. 9). AF64A/CC treated rats did not show a 
significant increase in enzyme activity. 
In the hippocampus, AChE activity was unaltered by 
AF64A/NGF treatment (0.38-3.08 nmol NGF) (f=0.90 p=0.489, 
df=5; fig. 10). AF64A/CC treated rats had a non-significant 
decrease (23% of control) of hippocampal AChE activity. 
Septal AChE activity was significantly changed (f=6.61, 
p=0.000, df=5) but, was less responsive to AF64A/NGF 
treatment than ChAT activity. AChE activity was signif-
icantly increased (p< 0.01) 171~ and 221% of control for the 
doses of 0.38 and 1.54 nmol NGF respectively (fig. 10) 
These increases were dose-dependent since there was a 
significant difference (p=0.047) between the level of 
activity in rats treated with 0.38 nmol and 1.54 nmol NGF. 
AF64A/CC and AF64A/NGF treated rats showed no change in 
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Fig. 10. AChE activity in the SHP of AF64A/NGF treated rats. 
VEH (water at pH 7.3) or AF64A (1.5 nmol/ventricle) was 
administered by i.c.v. injection. Rats were then infused 
with either CC (3.24 nmol) or NGF (0.38-3.08 nmol) 
continuously for 14 days. Each treatment group consisted of 
7-8 rats. *, p< 0.05 comparea with VEH/CC treated rats; **, 
p< 0.05 compared with AF64A/CC treatea rats and a, p< 0.05 
compared with AF64A/NGF 0.38 nmol. 
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GAD activity in either the hippocampus or septum (f=l.084, 
p=0.38, df=5 and f=l.88, p=0.121, df=5 respectively; fig. 
11) . 
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In striatal tissue, AF64A/CC treatment did not produce 
any significant change in ChAT activity compared with VEH/CC 
treated rats. AF64A/NGF treated rats, in contrast, showed a 
dose-dependent increase in ChAT activity (f=20.02, p=0.000, 
df=5). ChAT activity increased (p< 0.01) to 128% and 151% of 
VEH/CC respectively, for the 0.38 nmol and 3.08 nmol doses 
of NGF (fig. 12) and the level of enzyme activity at these 
doses were significantly different (p=0.01) from each other. 
AChE activity was unchanged in both the AF64A/CC and 
AF64A/NGF treated rats (f=0.70, p=0.624, df=5; fig. 13). 
Direct Comparison of the Effects of NGF in VEH and AF64A 
Treated Rats 
In the third experiment directly comparing NGF's affect 
in VEH and AF64A treated rats, sham operated and VEH/CC 
treated rats showed similar levels of enzyme activity in 
both the hippocampus and septum for ChAT, AChE, and GAD 
activity (p >0.05 by independent t-test). These two treat-
ments were grouped together into one control group (CONT) . 
95 
Fig. 11. GAD activity in the BHP of AF64A/NGF treated rats. 
VEH (water at pH 7.3) or AF6qA (1.5 nmol/ventricle) was 
administered by i.c.v. injection. Rats were then infused 
with either CC (3.24 nmol) or NGF (0.38-3.08 nmol) 
continuously for 14 days. Each treatment group consisted of 
7-8 rats. 
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Fig. 12. ChAT activity in the striatum of AF64A/NGF treated 
rats. VEH (water at pH 7.3) or AF64A (1.5 nmol/ventricle) 
was administered by i.c.v. injection. Rats were then infused 
with either CC (3.24 nmol) or NGF (0.38-3.08 nmol) 
continuously for 14 days. Each treatment group consisted of 
7-8 rats. *, p< 0.05 compared with VEH/CC treated rats; **, 
p< 0.05 compared with AF64A/CC treated rats and a, p< 0.05 
compared with AF64A/NGF 0.38 nmol. 
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Fig. 13. AChE activity in the striatum of AF64A/NGF treated 
rats. VEH (water at pH 7.3) or AF64A (l.5 nmol/ventricle) 
was administered by i.c.v. injection. Rats were then infused 
with either CC (3.24 nmol) or NGF (0.38-3.08 nmol) 
continuously for 14 days. Each treatment group consisted of 
7-8 rats. 
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In the hippocampus, the level of ChAT activity was 
significantly altered between treatment groups (f=l0.19, 
p=0.000, df=3). AF64A/CC produced a significant (p=0.007), 
27%, reduction in ChAT activity compared with VEH/CC treated 
rats. Rats treated with AF64A/NGF had only a 10% reduction 
in enzyme activity and this was not significantly different 
from either VEH/CC or AF64A/CC treated rats (p >0.05). 
VEH/NGF treated rats increased (p=0.003) their ChAT activity 
to 127% of control (fig. 14). In this experiment, ChAT 
activity changed significantly (f=36.82, p=0.000, df=3) in 
the septum. Septal ChAT activity was not changed by AF64A/CC 
but, was significantly (p=0.000) increased in both the 
AF64A/NGF and VEH/NGF treated rats by 211% and 148% of 
control, respectively. Although both the AF64A/NGF and 
VEH/NGF treated rats had increased septal ChAT activity, the 
level of ChAT activity was significantly (p=0.000) different 
between these two groups (fig. 14). 
In this third experiment, AChB activity significantly 
differed between treatment groups in both the hippocampus 
(f=ll.29, p=0.000, df=3) and septum (f=20.04, p=0.000, 
df=3). AChE activity in the hippocampus was significantly 
(p=0.000) decreased by 31% following AF64A/CC treatment 
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Fig. 14. Comparison of the effect of NGF in VEH and AF64A 
treated rats. Rats were treated with either CC or NGF for 14 
days. The control group (CONT) is composed of rats which 
were treated with CC alone or VEH/CC (see text for details). 
VEH (water at pH 7.3) or AF64A (1.5 nmol/ventricle) was 
administered by i.c.v. injection. Rats were then infused 
continuously for 14 days with either CC (3.24 nmol) or NGF 
(3.08 nmol). There were 14 rats in the control group and 6-8 
in all other groups. *, p< 0.05 compared with CONT treated 
rats; **, p< 0.05 compared with AF64A/CC treated rats and#, 
P< 0.05 compared with VEH/NGF. 
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compared with the activity in VEH/CC treated rats. AChE 
activity in AF64A/NGF treated rats was also significantly 
(p=0.000) decreased compared with VEH/CC treated rats. In 
contrast to the ChAT activity in these rats, the VEH/NGF 
treated rats did not exhibit a significant change in 
hippocampal AChE activity. Septal AChE activity was not 
changed in rats treated with AF64A/CC. AF64A/NGF and VEH/NGF 
treatment produced a 189% and 135% of control increase in 
septal AChE activity respectively (p< 0.01) (fig. 15). This 
increase in AChE activity was significantly (p=0.000) 
different between these two treatment groups. 
All three treatment groups (AF64A/CC, AF64A/NGF, and 
VEH/NGF) showed no change in GAD activity in either the 
hippocampus or septum (f=0.60, p=D.619, df=3 and f=0.40, 
p=0.756, df=3 respectively; fig. 16). 
Striatal ChAT activity was altered by the various 
treatment groups in this experiment (f=43.76, p=0.000, df=3) 
ChAT activity in striatal tissue was not changed by AF64A/CC 
but, was increased (p< 0.01) by both AF64A/NGF and VEH/NGF 
treatment (171% and 158% of control respectively; Fig. 17). 
These increases in enzyme activity were not different 
between the two treatment groups (p=0.13). 
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Fig. 15. Comparison of the effect of NGF in VEH and AF64A 
treated rats. Rats were treated with either CC or NGF for 14 
days. The control group (CONT) is composed of rats which 
were treated with CC alone or VER/CC (see text for details). 
VEH (water at pH 7.3) or AF64A (l.5 nmol/ventricle) was 
administered by i.c.v. injection. Rats were then infused 
continuously for 14 days with either CC (3.24 nmol) or NGF 
(3.08 nmol). There were 14 rats in the control group and 6-8 
in all other groups. *, p< 0.05 compared with CONT treated 
rats; **, p< 0.05 compared with AP64A/CC treated rats and#, 
P< 0.05 compared with VEH/NGP. 
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Fig. 16. Comparison of the effect of NGF in VEH and AF64A 
treated rats. Rats were treatea with either CC or NGF for 14 
days. The control group (CONT) is composed of rats which 
were treated with CC alone or VEH/CC (see text for details) . 
VEH (water at pH 7.3) or AF64A (1.5 nmol/ventricle) was 
administered by i.c.v. injection. Rats were then infused 
continuously for 14 days with either CC (3.24 nmol) or NGF 
(3.08 nmol). There were 14 rats in the control group and 6-8 
in all other groups. 
300 
> 250 ~ 
~ 
> -'"' ~ ~ ~ 
u e 200 
....... 
< -Q 
~ e 
= < -
..= 150 u 
100 
CONT AF64A/ 
cc 
* 
** 
AF64A/ 
NGF 
TREATMENT 
VEH/ 
NGF 
106 
Fig. 17. Comparison of the effect of NGF in the striatum of 
VEH and AF64A treated rats. Rats were treated with either CC 
or NGF for 14 days. The control group (CONT) is composed of 
rats which were treated with CC alone or VEH/CC (see text 
for details). VEH (water at pH 7.3) or AF64A (1.5 nmol/ 
ventricle) was administered by i.c.v. injection. Rats were 
then infused continuously for 14 days with either CC (3.24 
nmol) or NGF (3.08 nmol). There were 14 rats in the control 
group and 6-8 in all other groups. *, p< 0.05 compared with 
CONT treated rats and**, p< 0.05 compared with AF64A/CC 
treated rats. 
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AChE activity in the striaturn showed no change (f=l.18, 
p=0.331, df=3) after AF64A/CC, AF64A/NGF or VEH/NGF 
treatment compared with control treated rats (fig. 18). 
Effect of NGF on Weight Gain in Normal and AF64A Treated 
Rats 
The weights of all rats were measured. Table 2 
indicates that normal rats treated with NGF gained 
significantly less weight (8%-24%) than those treated with 
CC (32%) (f=S.95, p=0.001, df=4) after 14 days of treatment. 
In the AF64A/NGF dose response experiment, there was a 
significant difference in weight gain between treatment 
groups (f=7.38, p=0.000, df=S). AF64A/CC treated rats had 
weight gain similar to VEH/CC treated rats over the 14 day 
treatment period (table 3). Rats treated with AF64A/NGF had 
a marked attenuation in weight gain (only a 3-8% increase 
from their initial weight). All the AF64A/NGF treated rats, 
regardless of the dose of NGF administered, showed a 
significant difference in weight at the end of the 14 day 
treatment compared with either VEH/CC or AF64A/CC treated 
rats (p< 0.01). 
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Fig. 18. Comparison of the effect of NGF in VER and AF64A 
treated rats. Rats were treated with either CC or NGF for 14 
days. The control group (CONT) is composed of rats which 
were treated with CC alone or VEH/CC (see text for details) . 
VER (water at pH 7.3) or AF64A (1.5 nmol/ventricle) was 
administered by i.c.v. injection. Rats were then infused 
continuously for 14 days with either CC (3.24 nmol) or NGF 
(3.08 nmol). There were 14 rats in the control group and 6-8 
in all other groups. 
Table 2.-- Changes in the weight of normal rats 
treated with NGF over 14 days. 
TREATMENT WEIGHT ON DAY 7 WEIGHT ON DAY 14 
cc 111 (3. 82) 142 ( 1. 13) 
0.38 nmol 110 (3. 3 6) 138 ( 3. 63) 
0.77 nmol 103 (6. 56) 126 (6.58)* 
1. 54 nmol 111 (3. 47) 124 (6.71)* 
3.08 nmol 109 (3. 2 6) 115 (4.06)* 
Data are expressed as the % mean ± SEM of the rats' 
initial weight on day 1 which was 100% (100% for CC 
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on day 1 was 257 g). *, p< 0.05 compared with CC (3.24 nmol) 
treated rats. 
Table 3.-- Changes in the weight of AP64A/NGF treated rats. 
TREATMENT WEIGHT ON DAY 7 WEIGHT ON DAY 14 
VEH/CC 111 (3 - 6 5) 132 (3.85) 
AF64A/CC 110 (2.65) 132 (2.87) 
AF64A/0.38 nmol 109 (2.20) 108 (3.38)** 
AF64A/0.77 nmol 104 (1.94)'"' 108 (5.69)** 
AF64A/1.54 nmol 100 (4.62)'"' 103 (6.47)** 
AF64A/3.08 nmol 102 (5 - 71) 106 (5.50)** 
Data are expressed as the ~ mean ± SEM of the rats' 
initial weight on day 1 which was 100% (100% for VEH/CC 
on day 1 was 309 g). AF64A was administered i.c.v. at a dose 
of 1.5 nmol per ventricle. '"', p< 0.05; **, p < 0.01 compared 
with VEH/CC treated rats. 
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Similar to the dose-response experiments, AF64A/NGF 
treated rats in the direct comparison experiment also had an 
attenuation in weight gain compared with the control group 
(table 4) at days 7 and 14 (p=0.01 and 0.003). The VEH/NGF 
treated rats in this experiment showed a slight decrease in 
weight gain compared with the control group. 
Discussion 
The present study evaluated the action of several doses 
of NGF on cholinergic neurons of the SHP in normal rats as 
well as those treated with AF64A. 
Previous work investigating the action of NGF on 
cholinergic neurons in normal rats has been conflicting. NGF 
has been shown not change ChAT activity in normal rats while 
reversing decreases in enzyme activity induced by FF 
transection (Williams, Jodelis and Donald 1989; Hefti et al. 
1984) . In addition, ChAT imrnunoreactivity is not changed in 
normal rats treated with NGP (Gage et al. 1988). 
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Table 4.-- Changes in the weight of rats used in the direct 
comparison study. 
TREATMENT WEIGHT ON DAY 7 WEIGHT ON DAY 14 
Control 106 (0.71) 124 (1.64) 
AF64A/CC 109 (3.27) 125 (4.10) 
AF64A/NGF 98 (0.48)~*" 109 (2.65)** 
VEH/NGF 102 ( 1. 08) 118 (1.48) 
Data are expressed as the % mean ± SEM of the rats' 
initial weight on day 1 which was 100~ (100% for CC 
on day 1 was 356 g). AF64A was administered i.c.v. 
at a dose of 1.5 nmol per ventricle. **, p< 0.01 comp-
ared with control rats. 
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In contrast to these findings, several studies have shown 
that NGF administered to normal rats stimulates ChAT 
activity in both the septum and hippocampus (Vahlsing et al. 
1991; Rylett and Williams 1994; Fusco et al. 1989; Vantini 
et al. 1988; Williams 199la). 
The results of the current study concur with findings 
that normal, non-compromised cholinergic neurons of the SHP 
are responsive to exogenously administered NGF. Further, the 
action of NGF occurred in a dose-dependent manner. NGF 
administration clearly affected ChAT activity in normal rats 
while AChE activity did not change in NGF treated rats. 
These results are supported by previous studies showing that 
NGF administration to rats whose PF was unablated did not 
produce a change in AChE activity (Fusco et al. 1989; Hefti 
et al. 1984). These data indicate that NGF interacts with 
mature cholinergic neurons of normal adult rats. 
The current study indicates that high doses of NGF does 
not stimulate hippocampal cholinergic enzyme activity in 
AF64A treated rats. These data are in agreement with 
previous in vivo work which demonstrated that NGF 
administration, to AF64A treated rats, did not affect AF64A 
induced decreases in cholinergic phenotypic markers (Johnson 
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et al. 1988; Potter and Morrison 1991). In vitro, NGF has 
also been shown to reverse AF64A induced decreases of ChAT 
activity in rat brain reaggregate cultures (Atterwill and 
Meakin 1990). The current study, in conjunction with the 
current literature, indicate that NGFs action in vivo on the 
cholinergic terminals (hippocampal region) of AF64A treated 
rats is minimal. 
NGF did not alter AChE activity in the hippocampus of 
AF64A treated rats. AF64A/NGF treated rats had changes in 
septal AChE activity similar to the changes seen in ChAT 
activity of these animals. Although the pattern of response 
to NGF was similar, the increase in AChE activity was less 
(221% compared with 273% for ChAT) . This data indicates that 
the increases in both ChAT and AChE activity in the septum 
of AF64A/NGF treated are in contrast to NGFs action in 
normal rats where NGF only alters ChAT activity. 
In the present work, enzyme activity in GABAergic 
neurons was not altered by NGF administration to either 
normal or AF64A treated rats and suggests that NGF is 
selective for cholinergic neurons in the SHP. Previous work 
demonstrated that NGF administration did not alter FF 
transection induced changes in GAD-IR (Montero and Hefti 
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1988). In rats with cortical lesions, GAD activity in the 
SHP after i.c.v. infusion of NGF was also unaltered 
(Garofalo and Cuello 1994). The current study extended these 
results by administering NGF over a range of doses and 
found that, over this range (0.38-3.08 nmol), NGF did not 
alter GAD activity in the SHP. Further, the present work 
concurs with previous studies showing that AF64A does not 
alter hippocampal GAD activity (Reine et al. 1992; Calhoun, 
Myles, and Rylett 1986). 
The present study demonstrates that an interaction 
occurs in the SHP between the terminal and cell body of 
these neurons. Rats treated with AF64A/NGF demonstrated 
increases in both ChAT and AChE activity to levels of 273% 
and 221% of control, respectively. In contrast, normal rats 
treated with NGF had increases in their enzyme activities of 
149% for ChAT and 135% for AChE. Other studies have also 
found that rats with deficits in cholinergic phenotypic 
markers have increased sensitivity to NGF administration 
(Williams et al. 1989; Williams 1991a; Yunshao et al. 1992) 
Together with the current study, this indicates that when 
cholinergic neurons of the SEP are compromised, these 
neurons have an increased sensitivity to the effects of 
115 
exogenously administered NGF compared with neurons that are 
not compromised. The increased responsiveness of AF64A 
treated rats to NGF indicates that the action of this toxin 
at neuronal terminals (decrease of cholinergic enzyme 
activity in the hippocarnpus) affects the activity which 
occurs in the cell body (increased responsiveness to NGF in 
the septum) . The present work therefore provides a good 
model of neuronal integration by demonstrating the 
relationship between changes that occur in the hippocampus 
and septum. 
One possible explanation for the increased 
responsiveness of AF64A treated rats to NGF is that AF64A 
may increase the level of endogenous NGF in the SHP. Other 
noxious insults to the BHP such as lesions (Weskamp et al. 
1986; Lauterborn et al. 1994b; Scott et al. 1994; Lindvall 
et al. 1994; Conner et al. 1994i and Gall and Isackson 
1989); electrical stimulation (Ernfors et al. 1991); or 
kainic acid administration (Gall et al. 1991), have been 
shown to produce an increase in NGF, its mRNA and its 
receptors. An increase in endogenous NGF would result in a 
higher level of NGF available to the BHP cholinergic neurons 
of AF64A/NGF treated rats compared with that found in rats 
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treated with NGF alone. 
Another explanation could be that AF64A inhibits axonal 
transport. Previous work has shown that in both the CNS and 
PNS, AF64A, at high doses, inhibits axonal transport (Kasa 
and Hanin 1985) . If axonal transport is blocked by AF64A, 
one would expect an accumulation of the enzyme protein in 
the septum and a deficit in the hippocampus. This 
corresponds to the data in the present study in which AF64A 
treated rats had a robust increase in enzyme activity in the 
septum and no change in the hippocampus. In normals rats, 
changes (increase) in enzyme activity produced by NGF was 
evenly distributed in the SHP, as would be expected if 
axonal transport was functioning properly. 
The present work showed that cholinergic enzyme 
activity in the striatum was not altered by i.c.v. 
administration of 1.5 nmol AF64A. This is in agreement with 
work that has shown that i.c.v. injections of 2-3 nmol AF64A 
does not alter ACh levels (Potter et al. 1989) or ChAT and 
AChE activity (Leventer et al. 1985) in the striatum. In 
contrast, intrastriatal injection of 0.4 nmol AF64A produced 
a reduction in ChAT and AChE activity in the striatum 
(McGurk et al. 1987). 
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The current study indicates that ChAT activity in the 
striatum is responsive to NGP in a dose-dependent manner. 
Changes in cholinergic neuronal activity in the striatum 
after NGF administration have been reported previously. 
Several groups have demonstrated that i.c.v. administration 
of NGF increases cell body size (Vahlsing et al. 1991) and 
ChAT activity (Altar et al. 1992; Williams and Oostveen 
1992) . In the present study, the action of NGF on 
cholinergic enzyme activity in the striatum was confirmed 
and it was further demonstrated that this action was dose-
dependent. In addition, in this brain region, NGF increased 
enzyme activity in a similar manner to both AF64A/NGF and 
VEH/NGF treated rats indicating that the increased response 
to NGF in the septum of AP64A/NGF treated rats is AF64A-
dependent. 
Similar to previous work (Lapchak and Hefti, 1992; 
Williams 199lb; Williams and Oostveen 1992), NGF treated 
rats in the current study had an attenuation in normal 
weight gain compared with non-NGF treated rats. This lack of 
weight gain may be due to a decrease in food consumption 
(Williams 199lb). Similar to the sensitization that occurred 
in cholinergic enzyme activity of AF64A/NGF treated rats, 
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these rats were also more sensitive to the effects that NGF 
had on weight gain. Further, the AF64A/NGF group (1.54 nmol 
NGF) which had the least amount of weight gain, had the 
greatest increase in septal enzyme activity. These data 
further support the possibility that AF64A induces an 
increase in endogenous NGF. Such an increase, coupled with 
exogenously administered NGF, should result in less weight 
gain in AF64A treated rats than in normal rats treated with 
NGF. 
In conclusion, NGF administration to both normal and 
AF64A treated rats produced an increase in cholinergic 
enzyme activity. Furthermore, AF64A treated rats have an 
increased sensitivity to the effects of NGF on cholinergic 
neurons in the SHP. These findings raise the possibility 
that degenerating neurons in SDAT patients might also be 
more sensitive to NGF. 
CHAPTER V 
TEMPORAL ACTION OF NGF IN THE SBP OF NORMAL AND AF64A 
TREATED RATS, IN VIVO 
Summary 
When administered into the lateral ventricles, NGF 
increases cholinergic enzyme activity and expression in the 
SHP. This increase in enzyme activity occurs in both normal 
rats as well as those with decreased cholinergic phenotypic 
markers. NGF administration to normal rats over 14 days 
produces an increase in ChAT activity in the septum and 
hippocampus (Fusco et al. 1989). NGF's action on cholinergic 
enzyme activity in normal rats, when administered over 
shorter periods of time, has not been previously reported. 
In the present study, NGF was administered for 3 thru 28 
days to normal rats, as well as those treated with the 
neurotoxin, AF64A. AF64A/NGF treated rats had an increase of 
179% of control in septal ChAT activity after three days of 
continuous NGF administration. The level of septal ChAT 
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activity in AF64A/NGF treated rats peaked at 14 days (279~ 
of control) and decreased slightly (to 235% of control) by 
28 days. VEH/NGF treated rats had an increase in septal ChAT 
activity (147% of control) after seven days of continuous 
NGF administration and this activity remained elevated up to 
28 days. 
These data indicate that i.c.v. administration of NGF 
induces rapid changes in cholinergic phenotypic markers in 
the SHP of both normal and AF64A treated rats. 
Introduction 
Many studies have shown that in vivo, i.c.v. NGF 
administration produces changes in cholinergic phenotypic 
markers. These changes occur in both normal and FF 
transected rats. Fourteen day i.c.v. administration of NGF 
to normal, intact rats, increased ChAT activity in the 
septum and hippocampus (Fusco et al. 1989; Vantini et al. 
1988). Whether NGF's action on cholinergic neurons in normal 
rats also occurs with longer or shorter lengths of 
administration has not been previously determined. 
NGF attenuates the loss of cholinergic phenotypic 
markers such as ChAT-IR, AChE staining as well as ChAT and 
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AChE activity, in the septum and hippocampus of FF 
transected rats (Lapchak and Hefti 1991; Hefti 1986; Montero 
and Hefti 1988; Kromer et al. 1987; Williams, Jodalis and 
Donald 1989) . In these studies, NGF administration varied 
between 3 thru 28 days. The evaluation of NGF administration 
on decreased hippocampal cholinergic enzyme activity has 
only been done over a 21 day treatment period (Lapchak and 
Hefti 1991) . Evaluation of the action of NGF on hippocampal 
enzyme activity in rats with decreased cholinergic 
phenotypic markers over shorter time periods has not been 
previously determined. 
AF64A is a toxin which, when administered by i.c.v. 
injection and at specific doses, is selective for 
cholinergic neurons in the SHP. AF64A has been previously 
shown to reduce cholinergic enzyme activity (ChAT and AChE) 
as well as HAChT in the hippocampus (Potter et al. 1989; El 
Tamer et al. 1992; Chrobak et al. 1988; Chrobak et al. 1987; 
Ikegami et al. 1989; Opello 1993). Previous work with NGF in 
AF64A treated rats indicates that 14 day treatment does not 
alter AF64A induced reduction of hippocampal cholinergic 
phenotypic markers (Potter and Morrison 1991; Johnson et al. 
1988). Cholinergic enzyme actiYity in the septum of AF64A 
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treated rats has also been shown to be hyper-sensitive to 
the action of NGF (Willson and Hanin, in press) . Whether NGF 
administration for longer than 14 days (i.e. 28 days) 
produce changes in cholinergic enzyme activity in either 
normal or AF64A treated rats has not been previously 
determined. 
NGF administration for 14 days has been previously 
shown to attenuate the normal weight gain that occurs in 
rats (Lapchak and Hefti 1992; Williams and Oostveen 1992) 
Whether this attenuation in normal weight gain continues 
with longer periods of administration has not been 
investigated. 
The present study investigated the effects of i.c.v. 
NGF administration, over various lengths of time, on 
cholinergic enzyme activity in both normal and AF64A treated 
rats. In addition, changes in weight gain were also 
evaluated in these rats. The current study indicates that as 
early as three days after continuous NGF infusion to AF64A 
treated rats, a stimulation of enzyme activity occurs in 
cholinergic neurons of the SHP. This increase in activity 
remained even in rats treated with NGF continuously for 28 
days. In addition, NGF administration resulted in weight 
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loss after three days of continuous administration. Even 
after 28 days, the weight gain in NGF treated rats was not 
comparable to the weight gain that occurred in the control 
rats. 
Materials and Methods 
Animals 
Adult, male Sprague-Dawley rats (Zivic Miller 
Laboratories, Allison Park, PA.) weighing between 200-310 
grams were used for this study. The rats were housed two per 
cage in a room on a 12 hour light cycle and had access to 
food and water ad libitum. A total of 160 rats were used in 
this experiment. Rats treated with NGF for three days were 
weighed at the time of surgery and at the time of sacrifice. 
All other rats were weighed at the time of surgery and every 
seven days thereafter until they were killed. All rats were 
used under according to IACUC specifications. 
AF64A 
AF64A was prepared according to standard procedures 
(Fisher et al. 1982). Briefly, acetyl ethylcholine mustard 
hydrochloride (UCB, Belgium) was dissolved in water to a 
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concentration of 1 mM. This solution was adjusted to pH 11.5 
with sodium hydroxide (NaOH; 1M-6M) and stirred for 20 
minutes at room temperature. The solution was then adjusted 
to pH 7.3 with hydrochloric acid (HCl; 1M-6M) and stirred at 
room temperature for one hour. This solution was prepared 
fresh before each experiment and kept on ice. Preparation of 
AF64A in this manner produces 85-90~ cyclization of the 
aziridinium ring (Gill and Rang 1966; El Tamer et al. 1992) 
Surgical Procedures And Drug Treatment 
Rats were anesthetized with equitensin (3ml/kg) 
administered by intraperitoneal injection, placed into a 
stereotaxic apparatus (Kopf) and their skull was exposed. 
Either VEH (water, pH 7.3) or AF64A (1.5 nmol) was 
administered bilaterally, one side at a time, into the 
lateral ventricles at the coordinates of: -0.8 mm posterior, 
+/- 1.5 mm lateral, and -4.0 mm ventral to bregma (Paxinos 
and Watson 1986). One hour after the i.c.v. injection of 
either VEH or AF64A, a sterile cannula-osmotic pump assembly 
(Alza, Palo Alto, CA), filled with either cytochrome C (CC; 
a control protein) (40 µg; 3.24 nmol) or NGF (40 µg; 3.08 
nmol total) (Harlan Bioproducts, Indianapolis, IN) dissolved 
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in artificial cerebrospinal fluid (NaCl, 123 mM; CaC1 2 , 0.86 
mM; KCl, 3.0 mM; MgC1 2 , 0.89 rnM; NaHC03 , 25 mM; NaH2 P04 , 0.5 
mM and Na2HP04 , 0.25 rnM) containing l~ bovine serum albumin 
and pre-equilibrated for at least three hours in sterile 
saline at 37°C was implanted subcutaneously on the animal's 
back. The tip of the cannula was stereotaxically lowered 
into either the right or left lateral ventricle. The cannula 
was affixed to the skull, via an anchoring screw, with 
dental cement (Coralite Dental Products, Skokie, Il). The 
wound was closed and the rats were administered 0.3 ml 
(50 mg/ml) ampicillin subcutaneously. The NGF dose used was 
based on the increase in cholinergic enzyme activity at this 
dose in chapter IV. In this experiment, the four treatment 
groups; VEH/CC, AF64A/CC, AF64A/NGF and VEH/NGF were treated 
continuously for either 3, 7, 14 or 28 days. Rats treated 
over 28 days had their pumps replaced after 14 days with 
fresh pumps containing the identical substance initially 
administered. At the end of the treatment period the rats 
were killed by decapitation and the brains were dissected on 
ice. The hippocampal and septal tissue was immediately 
placed on dry ice and subseguently stored at -70°C. 
An additional group of rats, containing all four 
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treatment groups were treated similarly to the rats in the 
28 day time period except that, NGF was administered for 
only 14 days. On day 14, all rats had their pumps replaced 
with CC filled pumps. The CC was administered for an 
additional 14 days. Rats in this 14 day NGF treatment/28 day 
survival paradigm were killed on day 28 and the hippocampus 
and septum were removed as described above. There were seven 
to eight rats in each group at each time point since six 
rats died during the course of the experiment. 
ENZYME ASSAY 
Tissue preparation 
The hippocampus and septum were thawed in ice cold 
sodium phosphate buffer 75 mM, pH 7.4, (1 ml for hippocampal 
tissue and 0.6 ml for septal tissue) and homogenized (20 
sec. @ setting 5 on a Polytron homogenizer model # PT 
10/35). 
ChAT activity 
The ChAT assay followed the Fonnum method (1975). In 
brief, 10 µl of tissue homogenate was added to 10 µl of 
buffer substrate [cold sodium phosphate, 75 mM pH 7.4; NaCl, 
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600 mM; MgC1 2 , 40 mM; eserine, 2.0 mM; bovine serum albumin, 
0.05%; choline-iodide, 10 mM; and [3H]acetyl coenzyme A, 
0.87 mM (= 20 mCi/mmol)]. This mixture was then incubated 
for 30 minutes at 37°C and the tubes placed on crushed ice 
following incubation. One hundred and fifty µl of sodium 
tetraphenylboron solution (75 mg/ml in 3-heptanone) was 
added to each tube and the tubes were vortexed and 
centrifuged. After centrifugation, 100 µl of the organic 
(top) layer was removed and placed into scintillation vials. 
Ten milliliters of scintillation cocktail was added and the 
vials were counted using liquid scintillation spectrometry. 
The level of ChAT activity was measured by subtracting the 
disintegrations per minute (dpm) in the blank tubes (without 
the tissue) from the dpm in the tubes with tissue. 
AChE activity 
The AChE assay is similar to the ChAT assay, but with 
the following modifications (Leventer et al. 1985). Tissue 
homogenate (10 µl) was added to 20 µl of buffer substrate 
[cold sodium phosphate buffer, 75mM, pH 7.0; AChI, lOmM and 
[ 3H]ACh iodide 10 mM (= 8 mCi/mmol)]. This mixture was 
incubated for 20 minutes at 37°C and the tubes were then 
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placed into crushed ice. Ice cold water (30 µl) was then 
added to each tube followed by 150 µl sodium tetraphenyl-
boron solution (75 mg/ml in 3-heptanone) . The tubes were 
then vortexed, centrifuged, and frozen for 30 minutes at 
-20°c. When removed from the freezer the organic (top) layer 
was discarded and the aqueous (bottom) layer thawed. Thirty 
µl of this aqueous layer was placed into scintillation vials 
and 10 ml of scintillation cocktail was added. These vials, 
along with blank tubes (assay without tissue substrate), 
were counted using a liquid scintillation spectrometer. The 
level of AChE activity was calculated by subtracting the dpm 
in the blank tubes from the dpm in the assay tubes with 
tissue. 
Protein Determination 
Tissue protein levels were assessed by the method of 
Lowry et al. (1951) for both the ChAT and AChE assays. 
Statistical Analysis 
The level of enzyme activity in the rats is expressed 
as either nmol/mg/hr or % control. The values indicated are 
means ± SEM of 7-8 rats per treatment group at each time 
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point. The data were analyzed by two way ANOVA followed by 
post-hoc analysis (Fisher LSD). The changes in the weights 
of the rats are expressed as the % mean ± SEM of the rats' 
initial weight. The data were analyzed by ANOVA with post-
hoc analysis (Fisher LSD) . The data from the VEH/CC and 
AF64A/CC treated rats in the 14 day NGF treatment/28 day 
survival paradigm were combined with the 28 day continuously 
treated rats for purposes of statistical analysis and 
therefore each treatment group (VEH/CC or AF64A/CC) 
contained 15 rats. 
Results 
In the hippocarnpus, there was a significant main effect 
of treatment group (f=45.53, p=0.000, df=4) and length of 
NGF administration (f=12.21, p=0.000, df=4) on ChAT 
activity. There was no interaction between the treatment 
group and the length of NGP administration (f=l.73, p=0.067, 
df=4). ChAT activity was significantly reduced (p< 0.01) in 
the hippocampus of AF64A/CC treated rats at 3, 7, 14 and 28 
days. AF64A/CC treatment decreased ChAT activity to 45%, 
58%, 63% and 71% of control (VEH/CC) for these times 
respectively (fig. 19). 
130 
* 
50 
** > ~ 40 
~ 
> 'I:' ~ ~ ~ 30 u e 
< ;::;;;; = ~ e 
= < - 20 
..= 
u 
* # 10 * 
0 7 14 21 28 
0 VER/CC 
a AF64A/CC DAYS 
• AF64A/NGF 
• VEH/NGF 
Fig. 19. ChAT activity was measured in the hippocampus. VEH 
(water) or AF64A (1.5 nmol/ventricle) was injected into the 
lateral ventricle followed by continuous administration of 
CC (3.24 nmol; 40 µg) or NGF (3.08 nmol; 40 µg) for either 
3, 7, 14 or 28 days. There were 7-8 rats per groups at each 
time point. *, p< 0.05 compared with VEH/CC; **, P< 0.05 
compared with AF64A/CC and #,p< 0.05 compared with VEH/NGF. 
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AF64A/NGF treated rats had similar declines in ChAT activity 
with the exception of rats treated for 28 days. At the 28 
day time point, hippocampal ChAT activity increased to 107% 
of control and was significantly greater (P=0.003) than the 
level of activity in AF64A/CC treated rats. Hippocampal ChAT 
activity in VEH/NGF treated rats increased significantly (p< 
0.05) by 34% and 26% of control at 7 and 28 days respec-
tively. The enzyme activity in all treatment groups of rats 
surviving 28 days was significantly (p< 0.05) greater 
compared with those surviving three days. 
In the septum, a significant difference was found in 
ChAT activity between the treatment groups (f=48.45, p=0.000 
df=3) but, not the various lengths of NGF administration 
(f=l.52, p=0.20, df=4). The interaction (f=l.57, p=0.108, 
df=l2) between treatment group and length of NGF 
administration was also non-significant. Septal ChAT 
activity was significantly increased (p< 0.01) in AF64A/NGF 
treated rats regardless of the length of treatment (fig. 
20). This increase in septal ChAT activity (179% of control) 
began at day 3 and peaked at day 14 (279% of control) . Rats 
treated for 28 days with AF64A/NGF showed a non-significant 
reduction in ChAT activity (reduced to 235% of control) . 
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Fig. 20. ChAT activity was measured in the septum. VEH 
(water) or AF64A (1.5 nmol/ventricle) was injected into the 
lateral ventricle followed by continuous administration of 
CC (3.24 nmol; 40 µg) or NGP (3.08 nmol; 40 µg) for either 
3, 7, 14 or 28 days. There were 7-8 rats per groups at each 
time point. *, p< 0.05 compared with VEH/CC; **, P< 0.05 
compared with AF64A/CC and #, p< 0.05 compared with VEH/NGF. 
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AF64A/CC treatment alone produced a non-significant increase 
(132% of control) in septal ChAT activity seven days after 
CC administration. At all other time points, ChAT activity 
in this treatment group remained at control levels. NGF 
alone (in VEH/NGF treated rats) increased septal ChAT 
activity (p< 0.05) 147%, 144% and 159% of control in rats 
treated for 7, 14 and 28 days respectively. The level of 
ChAT activity in VEH/NGF treated rats was significantly 
(p< 0.05) lower than in the AF64A/NGF treated at all time 
points. 
In the hippocampus there was a significant difference 
in AChE activity among the various treatment groups 
(f=24.87, p=0.000, df=3). The length of treatment did not 
alter hippocampal AChE activity (f=l.76, p=0.139, df=4). 
Across all treatment times, AF64A/CC significantly reduced 
(p< 0.01) (from 45%-63% of control for 3 and 28 days 
respectively) enzyme activity (fig. 21). Acetylcholin-
esterase activity in AF64A/NGF treated rats was similar, 
over the entire 28 days, to levels in AF64A/CC treated rats. 
Acetylcholinesterase activity in the VEH/NGF treated rats 
(83%-109% of control) was not significantly different from 
control rats. 
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Fig. 21. AChE activity was measured in the hippocampus. VEH 
(water) or AF64A (1.5 nmol/ventricle) was injected into the 
lateral ventricle followed by continuous administration of 
CC (3.24 nmol; 40 µg) or NGF (3.08 nmol; 40 µg) for either 
3, 7, 14 or 28 days. There were 7-8 rats per groups at each 
time point. *, p< 0.05 compared with VEH/CC; **, P< 0.05 
compared with AF64A/CC and#, p< 0.05 compared with VEH/NGF. 
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In the septum, AChE activity was significantly 
different among the treatment groups (f=28.04, p=0.000, 
df=3) but did not change with different lengths of treatment 
(f=l.05, p=0.38, df=4). Septal AChE activity in AF64A/NGF 
treated rats increased significantly (p< 0.01) after 14 and 
28 days of treatment (227% and 211% of control respectively) 
but, the level of enzyme activity at 3 and 7 days was 
unchanged (fig. 22). As with ChAT activity in AF64A/NGF 
treated rats, AChE activity peaked at day 14 and this 
increase began to decrease by 28 days. Septal AChE activity 
in the AF64A/CC and VEH/NGF treated rats was not 
significantly different at the 3, 7, or 14 day time point 
compared with control rats. Rats treated with VEH/NGF for 28 
days had a significant (p=0.028) increase in activity 
compared with controls. In addition, septal AChE activity in 
AF64A/NGF treated rats was significantly greater (p< 0.01) 
at 14 and 28 days than the activity in VEH/NGF treated rats. 
In rats treated with NGF for 14 days and then allowed 
to survive an additional 14 days (28 days survival 
paradigm), there was a significant change in ChAT activity 
between treatment groups (f=7.43, p=0.000, df=3). 
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Fig. 22. AChE activity was measured in the septum. VEH 
(water) or AF64A (1.5 nmol/ventricle) was injected into the 
lateral ventricle followed by continuous administration of 
CC (3.24 nmol; 40 µg) or NGF (3.08 nmol; 40 µg) for either 
3, 7, 14 or 28 days. There were 7-8 rats per groups at each 
time point. *, p< 0.05 compared with VEH/CC; **, P< 0.05 
compared with AF64A/CC and#, p< 0.05 compared with VEH/NGF. 
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ChAT activity was significantly (p< 0.01) decreased in 
hippocampus of AF64A/CC and AF64A/NGF treated rats (fig. 
23). VEH/NGF treatment did not alter ChAT activity compared 
with VEH/CC treated rats. Hippocampal ChAT activity in rats 
treated with AF64A/NGF for 14 days and allowed to survive an 
additional 14 days was significantly (p=0.001) different 
from the level of activity in rats treated with NGF for 28 
days continuously. The continuously treated rats increased 
their ChAT activity (to 107% of control) while the level of 
ChAT activity in rats treated for only 14 days remained 
decreased (63% of control) . 
There was a main effect of treatment group in septal 
ChAT activity (f=13.13, p=0.000, df=3). In both the 
AF64A/NGF or VEH/NGF treatment groups there was no 
difference in septal ChAT activity between rats in the 14 
day NGF treatment/28 day survival paradigm and those treated 
for 28 days continuously. Rats in the 14 day NGF 
treatment/28 day survival paradigm treated with AF64A/NGF 
had a significant (p=0.000) increase (201% of VEH/CC) in 
septal ChAT activity (fig. 24). 
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Fig. 23. ChAT activity in the hippocampus of rats in a 28 
day continuous NGF treatment paradigm and rats in a 14 day 
NGF administration/28 day total survival paradigm. VEH 
(water) or AF64A (1.5 nmol/ventricle) was injected into the 
lateral ventricle followed by administration of CC (3.24 
nmol; 40 µg) or NGF (3.08 nrnol; 40 µg} for 28 days 
continuously or 14 days. Values from the VEH/CC and AF64A/CC 
treated rats were combined. There are 15-16 rats in the 
VEH/CC and AF64A/CC treated groups. There are seven-eight 
rats in all other groups. *, P< 0.05 compared with VEH/CC; 
#, p< 0.05 compared with VEH/NGP and##, p< 0.05 compared 
with 28 day treated rats. 
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Fig. 24. ChAT activity in the septum of rats in a 28 day 
continuous NGF treatment paradigm and rats in a 14 day NGF 
administration/28 day total survival paradigm. VEH (water) 
or AF64A (1.5 nmol/ventricle) was injected into the lateral 
ventricle followed by administration of CC (3.24 nmol; 40 
µg) or NGF (3.08 nmol; 40 ~g) for 28 days continuously or 14 
days. Values from the VEH/CC and AF64A/CC treated rats were 
combined. There are 15-16 rats in the VEH/CC and AF64A/CC 
treated groups. There are seven-eight rats in all other 
groups. *, p< 0.05 compared with VEH/CC; **, p< 0.05 
compared with AF64A/CC and#, p< 0.05 compared with VEH/NGF 
treated rats. 
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AChE activity in the hippocampus of rats in the 14 day 
NGF treatment/28 day survival paradigm were significantly 
different among treatment groups (f=B.51, p=0.000, df=3). 
AChE activity was significantly (p< 0.01) reduced in the 
hippocampus of AF64A/CC and AF64A/NGF (to 63% and 53% of 
VEH/CC respectively) rats (fig. 25). The AF64A/CC and 
AF64A/NGF treated rats did not differ in hippocampal AChE 
activity. Further, there was no difference between the two 
treatment paradigms NGF alone (VEH/NGF) did not increase 
AChE activity in either of the two treatment paradigms. 
Septal AChE activity was significantly different among 
the four treatment groups (f=16.21, p=0.000, df=3). Septal 
AChE activity in rats treated with AF64A/NGF for 14 days and 
then allowed to survive an additional 14 days increased 
significantly (p=0.000) (235~ of VEH/CC) compared with VEH/CC 
and AF64A/CC treated rats (fig. 26). This change in septal 
AChE activity was similar to that in rats treated with 
AF64A/NGF continuously for the entire 28 days. The level of 
septal AChE activity in rats treated with VEH/NGF in the 14 
day treatment/28 days survival paradigm did not signif-
icantly change and was similar to that found in rats treated 
with NGF continuously for 28 days. 
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Fig. 25. AChE activity in the hippocampus of rats in a 28 
day continuous NGF treatment paradigm and rats in a 14 day 
NGF administration/28 day total survival paradigm. VEH 
(water) or AF64A (1.5 nmol/ventricle) was injected into the 
lateral ventricle followed by administration of CC (3.24 
nmol; 40 ~g) or NGF (3.08 nmol; 40 µg) for 28 days 
continuously or 14 days. Values from the VEH/CC and AF64A/CC 
treated rats were combined. There are 15-16 rats in the 
VEH/CC and AF64A/CC treated groups. There are seven-eight 
rats in all other groups. *, p< 0.05 compared with VEH/CC 
and#, p< 0.05 compared with VEH/NGF. 
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Fig. 26. AChE activity in the septum of rats in a 28 day 
continuous NGF treatment paradigm and rats in a 14 day NGF 
administration/28 day total survival paradigm. VEH (water) 
or AF64A (1.5 nmol/ventricle) was injected into the lateral 
ventricle followed by administration of CC (3.24 nmol; 40 
µg) or NGF (3.08 nmol; 40 µg) for 28 days continuously or 14 
days. Values from the VEH/CC and AF64A/CC treated rats were 
combined. There are 15-16 rats in the VEH/CC and AF64A/CC 
treated groups. There are seven-eight rats in all other 
groups. *, p< 0.05 compared with VEH/CC; and#, p< 0.05 
compared with VEH/NGF. 
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At the time of surgery, all rats had similar weights 
(f=0.93, p=0.428, df=3). After three days of treatment, the 
AF64A/NGF and VEH/NGF treated rats significantly (p< 0.01) 
decreased their weight compared with VEH/CC treated rats 
(table 5) . Similar to the VEH/CC treated rats, AF64A/CC 
treated rats maintained their weight (95%) compared with 
their initial weight. By day seven, all treatment groups 
showed increased weight gain and all rats increased their 
weight over the 28 days of treatment. Although the AF64A/NGF 
and VEH/NGF treated rats gained weight, they still weighed 
significantly less than VER/CC treated rats at all time 
points (P< 0.05). In addition, rats treated with AF64A/NGF 
or VEH/NGF for 14 days and then allowed to survive an 
additional 14 days (28 days total) had significantly 
(p< 0.05) less weight gain on day 21 than VEH/CC treated 
rats . By day 28, their weight gain was comparable to VEH/CC 
treated rats (table 5) . This differed from rats treated 
continuously with NGF since they which had significantly 
(p< 0.01) less weight gain than VEH/CC treated rats. In both 
the 14 day NGF treatment/28 day survival paradigm and the 28 
day NGF continuously treated rats, there was no significant 
difference between the VEH/CC and AF64A/CC treated rats. 
Table 5.-- Changes in Weight over Time by Treatment Groups 
TREATMENT GROUPS 
VEH/CC AF64A/CC AF64A/NGF VEH/NGF 
3 days 98 (l.26) 95 (2.34) 89 (2.68)** 92(2.10 )** 
7 days 115 (1.19) 109 (1.48) 102 (l.45) ** 110 (1.12)** 
14 days 137 (1. 80) 132 (2. 29 110 (2.59)** 120 (3.19)** 
21 days 155 (3.61) 148 ( 3. 71) 125 (6.57)** 140 (5.87)** 
28 days 172 (4. 80) 166 ( 4. 64) 145 (8.57)** 155 (7.11)** 
14 days NGF/ 28 days survival rats 
21 days 155 (3.61) 148 (3.71) 136 (5.31)** 145 (6.06)* 
28 days 172 (4.80) 166 (4.64) 160 (6.04) 168 ( 8. 11) 
Data are represented as the mean ± SEM % of the rats' initial weight at the time of 
surgery. * P < 0.05 and ** p < 0.01 compared with the VEH/CC rats. 
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Discussion 
In the present study, septal ChAT activity in AF64A 
treated rats is hyper-sensitive to NGF as early as three 
days after the beginning of treatment and continues up to 28 
days. After seven days of AF64A/NGF treatment, a large 
increase in ChAT activity which peaked at day 14 was found. 
Septal AChE activity in AF64A treated rats was also hyper-
sensitive to NGF, but this sensitivity took longer to occur 
(14 days) . AF64A treated rats, regardless of whether their 
treatment was followed by CC or NGP administration, had a 
decrease in hippocampal cholinergic enzyme activity. These 
results agree with previous work showing that AF64A acts on 
the cholinergic terminals in the hippocampus and reduces 
cholinergic enzyme activity, BAChT, and ACh levels (El Tamer 
et al. 1992; Potter and Morrison 1991; Fisher et al. 1982). 
The reduction in enzyme activity occurred as early as three 
days after AF64A treatment. Previous work has shown that two 
days after AF64A injection, ACh levels are reduced 50% in 
the hippocampus (Hortnagl et al. 1987a). Reduction of 
hippocampal ChAT and AChE activity, as well as HAChT, 
occurred four days after AF64A treatment (El Tamer et al. 
1992). In the present study, AF64A induced decreases in 
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hippocampal enzyme activity were not reversed after either 
3, 7 or 14 days of continuous NGF administration. In 
contrast, the AF64A/NGF rats showed a large increase in 
hippocampal enzyme activity between 14 and 28 days which 
resulted in a complete recovery of ChAT activity by 28 days. 
AF64A treated rats, continuously administered NGF for 28 
days, had a higher level of hippocampal ChAT activity 
compared with AF64A/CC treated rats and suggests that NGF 
can accelerate the recovery of cholinergic enzyme activity 
that occurs in AF64A treated rats at longer time points (El 
Tamer et al. 1992). 
The temporal changes in hippocampal and septal ChAT 
activity in the current study are consistent with the 
concept that, ChAT mRNA is localized in the septum but not 
the hippocampus (Ibanez, Ernfors and Persson 1991; 
Cavicchioli et al. 1991) and therefore, the ChAT protein 
must be antrogradely transported to the terminals in the 
hippocampus. The increase in septal ChAT activity prior to 
(between 7 and 14 days) changes in hippocampal activity 
(between 14 and 28 days) in AF64A/NGF treated rats suggest 
that, recovery of hippocampal ChAT activity after 28 days of 
NGF administration may be due to the stimulation of ChAT 
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synthesis in the septum. 
Rats treated with VEH/NGF had an increase in ChAT 
activity, but not AChE activity, in both the septum and 
hippocampus. In both regions, the increases in ChAT activity 
occurred simultaneously after seven days of continuous NGF 
administration. In comparison, 14 day administration of NGF 
to normal rats has been shown to produce an increase in ChAT 
activity in the septum and hippocampus (Fusco et al. 1989; 
Vantini et al. 1988). NGF administration to normal rats did 
not alter AChE activity (Fusco et al. 1989; Vantini et al. 
1988) . The data in the present study indicate that, in 
addition to increasing the sensitivity of cholinergic 
neurons of the SHP to exogenous NGF, AF64A treatment also 
reduces the length of NGF administration necessary to 
stimulate ChAT activity. 
Rats treated with NGF for 14 days and then allowed to 
survive an additional 14 days had a reduction in hippocampal 
ChAT and AChE activity in both AF64A/NGF and AF64A/CC 
treated rats. AF64A/NGF treated rats in this 14 days 
treatment/28 day survival paradigm had a decreased level of 
hippocampal enzyme activity while rats continuously treated 
with NGF for 28 days had levels of enzyme activity similar 
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to control. In FF transected rats, continuous NGF 
administration is necessary for recovery of AChE positive 
cells in the septum. If NGF treatment is discontinued, but 
the rats allowed to survive an additional four weeks, AChE 
staining returns to levels similar to rats with FF 
transections alone (Montero and Hefti 1988) . In addition, 
when NGF administration to an Alzheimer patient was 
discontinued in after three months of treatment, improve-
ments in nicotinic binding and memory were no longer evident 
(Olson et al. 1992). These data suggest that once NGF 
administration is discontinued, changes in cholinergic 
phenotypic markers do not persist and that continuous 
administration is necessary. 
Attenuation of weight gain in NGF treated rats occurred 
after three days of administration and are probably due to 
changes in food consumption. NGF administration decreased 
food intake in rats as early as five days after the initia-
tion of NGF infusion (Williams 1991). NGF's effect on 
attenuating normal weight gain was greater in AF64A/NGF 
treated rats than in VEH/NGF treated rats and further 
suggests that AF64A treated rats are hypersensitivity to 
exogenous NGF. Differences between AF64A/NGF and VEH/NGF 
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treated rats cannot be accounted for by AF64A administration 
alone since, AF64A/CC treated rats had weight gains 
comparable to VEH/CC treated rats. In addition, the 
attenuation in weight gain is NGF dependent since rats 
treated with NGF for 14 days, but allowed to survive for 28 
days, did not differ significantly in weight gain from 
VEH/CC treated rats. This is not unexpected since normal or 
FF transected rats treated with NGF over 14 days and then 
allowed to survive an additional 14 days had increased 
weight gain after NGF administration was discontinued 
(Williams 199lb) . 
The present study demonstrated that AF64A treated rats 
have increased sensitivity to NGF, compared with VEH/NGF 
treated rats, as early as three days after NGF administra-
tion is initiated. Further, this increase in enzyme activity 
remained for up to 28 days. Further, if NGF treatment is 
discontinued at 14 days, some of its actions (recovery in 
the hippocampus and attenuation of weight gain) do not 
persist after an additional 14 days. This indicates that in 
vivo, NGF treatment must be continuous in order to stimulate 
the recovery of AF64A induced decreases in cholinergic 
phenotypic markers. 
CHAPTER VI 
EFFECT OF BDNF ON THE SEPTO-HIPPOCAMPAL PATHWAY OF NORMAL 
AND ETHYLCHOLINE MUSTARD AZIRIDINIUM {AF64A) TREATED RATS. 
Summary 
In the present study, i.c.v. administration of BDNF 
increased ChAT activity in the septum of AF64A (1.5 
nmol/ventricle) treated rats. This response was dose 
dependent since enzyme activity increased only in rats 
treated with higher doses but not those treated with lower 
doses. BDNF at doses of 0.8 nmol and 8.0 nmol produced a 
126% of control increase in septal ChAT activity. Although 
these two doses of BDNF in AF64A treated rats increased 
cholinergic enzyme activity in the SHP, they did not affect 
GAD activity. In normal rats, BDNF treatment did not affect 
either cholinergic (ChAT and AChE) nor GABAergic (GAD) 
enzyme activity. This indicates that, in these experiments, 
BDNF selectively acted on cholinergic neurons which were 
affected by AF64A. 
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Introduction 
Cholinergic neurons of the SHP are responsive to NGF 
(for review see Levi-Montalcini 1987). Although NGF was the 
first NTF isolated and is the most characterized, other 
NTF's have now been isolated. One of these NTFs is BDNF 
(Barde et al. 1982). Since its discovery, BDNF and its mRNA 
have been localized to the dentate gyrus and cornu Ammonis 
region of the hippocampus (Phillips et al. 1990; Kokaia et 
al. 1993; Ernfors et al. 1990a). Further, the high affinity 
receptor for BDNF, TrkB, is also localized to the hippo-
campus (Kokaia et al. 1993) and septum (Altar et al. 1994c). 
The structural similarities between BDNF and NGF 
(Leibrock et al. 1989) indicate that BDNF, like NGF, might 
act on cholinergic neurons in the SHP. In vitro work has 
confirmed that BDNF acts on cholinergic neurons. BDNF 
administration increases cholinergic phenotypic markers such 
as AChE staining, ChAT activity, and HAChT in septal cell 
cultures (Alderson et al. 1990; Nonomura and Hatanaka 1992; 
Knusel et al. 1992). 
Recent work has evaluated the in vivo administration of 
BDNF to FF transected rats and whether it can prevent the 
loss of cholinergic neurons and their neuronal markers. 
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Several studies have shown that i.c.v. or intraseptal BDNF 
administration to rats can prevent FF transection induced 
cholinergic cell loss in the septum (Knusel et al. 1992; 
Morse et al. 1993). In contrast, other studies indicate that 
i.c.v. administration of BDNF does not reverse decreases in 
cholinergic phenotypic markers induced by FF transection 
(Lapchak et al. 1992; Koliatsos et al. 1994). Therefore, 
whether in vivo administration of BDNF affects cholinergic 
neurons of the SHP is still unclear. 
Although BDNF may be able to reverse the reduction of 
cholinergic phenotypic markers that occurs in FF transected 
rats, its action on normal, intact neurons has not been well 
studied. The administration of a single dose (10 µg/week) of 
BDNF to normal rats has been shown not to change septal ChAT 
enzyme activity (Koliatsos et al. 1994). If BDNF is to be 
considered as a potential therapeutic agent for neurodegen-
erative diseases, a complete evaluation of its action on 
cholinergic neurons of normal rats, at a variety of doses, 
is necessary. 
AF64A is a toxin which has been shown to be selective, 
in a dose dependent manner, for cholinergic neurons in the 
SHP (El Tamer et al. 1992; Hortnagl et al. 1987a,b). Using 
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this toxin, the ability to of BDNF reverse or prevent 
changes in cholinergic phenotypic markers in the SHP after 
AF64A administration can be assessed. In addition, 
cholinergic neurons of the SHP have been previously shown to 
be more responsive to NGF after AF64A treatment (Willson and 
Hanin, in press) . Whether SHP cholinergic neurons of AF64A 
treated rats are also more responsive to BDNF treatment is 
unknown. 
In the present work, the in vivo effects of BDNF on 
cholinergic enzyme activity in the SHP of normal and AF64A 
treated rats were evaluated. Further, in order to evaluate 
whether BDNFs action is restricted to cholinergic neurons or 
a more generalized effect of neuronal stimulation, the 
activity of the GABAergic synthesizing enzyme, GAD, was also 
evaluated. 
Materials and Methods 
Animals 
Adult, male Sprague-Dawley rats (Zivic Miller 
Laboratories, Allison Park, PA.) weighing between 
218-372 grams were used for this study. A total of 88 rats 
were used in this study. The rats were housed two per cage 
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in a room on a 12 hour light cycle and had access to food 
and water ad libitum. The rats were weighed at the time of 
surgery and once every week till they were sacrificed. 
AF64A 
AF64A was prepared according to standard methods 
(Fisher et al. 1982). Acetyl ethylcholine mustard 
hydrochloride (UCB, Belgium) was dissolved in water to a 
concentration of 1 mM. This solution was adjusted to pH 11.5 
with sodium hydroxide (NaOH; 1M-6M) and stirred for 20 
minutes at room temperature. The solution was then adjusted 
to pH 7.3 with hydrochloric acid (HCl; 1M-6M) and stirred at 
room temperature for one hour. This solution was prepared 
fresh before each experiment and kept on ice. Preparation of 
AF64A in this manner produces 85-90% cyclization of the 
aziridinium ring (Gill and Rang 1966; El Tamer et al. 1992). 
Surgical Procedures and Drug Treatment 
All rats were anesthetized with equitensin (3ml/kg) 
administered by intraperitoneal injection. The rats were 
placed into a stereotaxic apparatus (Kopf) and their skull 
was exposed. 
155 
Dose response studies 
In the dose-response experiment in normal rats, rats 
were sham operated by having two needles (26 gauge) lowered 
into the lateral ventricles through two holes drilled at the 
coordinates of: -0.8 mm posterior, +/- 1.5 mm lateral, and -
4.0 mm ventral to bregma (Paxinos and Watson 1986). The 
needles were left in place for one minute and then removed. 
A sterile cannula-osmotic pump assembly (Alza, Palo Alto, 
CA) was filled with either cytochrome C (CC; a control 
protein) or recombinant BDNF (a gift from Regeneron 
Pharmaceuticals, Tarrytown, NY) dissolved in artificial 
cerebrospinal fluid (NaCl, 123 mM; CaC12 , 0.86 mM; KCl, 3.0 
mM; MgC12 , 0. 89 mM; NaHC03 , 25 mM; NaH2 P04 , 0. 5 mM; and Na2HP04 , 
0.25 mM) containing 1% bovine serum albumin. This level of 
serum albumin was recommended by Regeneron when using lower 
doses of BDNF as in the current study. The cannula-pump 
assembly had been pre-equilibrated for at least three hours 
in sterile saline at 37°C. The osmotic pump was implanted 
subcutaneously on the animal's back and the tip of the 
cannula was stereotaxically lowered into either the right or 
left lateral ventricle. This was affixed to the skull, via 
an anchoring screw, with dental cement (Coralite Dental 
Products, Skokie, Il). The wound was closed and the rats 
were administered 0.3 ml (50 mg/ml) ampicillin 
subcutaneously. In this experiment 40 rats were used 
although two died before completion of the experiment. 
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In the dose-response experiment with AF64A treated 
rats, the control rats (VER/CC) had water at pH 7.3 as 
vehicle (VEH) injected into the lateral ventricles (see 
coordinates given above) . Rats in the AF64A treatment groups 
had AF64A (1.5 nmol/ventricle) injected into their lateral 
ventricles. These injections were bilateral, one side 
injected at a time, at a rate of 0.5 ~l per minute. The 
cannula-pump assembly was implanted as described for the 
normal rats. Of the 48 rats in this experiment, two were 
eliminated from the analysis due to post-surgical 
complications and two rats died during the experiment. 
In both experiments, CC (99 ~g; 8.0 nmol total) or BDNF 
(0.099-99 µg; 0.008-8.0 nmol total) was administered 
continuously for 14 days. These doses were chosen because 
previous work has shown that 90 µg BDNF can stimulate ChAT-
IR in FF transected rats (Knusel et al. 1992). At the end of 
the treatment the rats were sacrificed by decapitation and 
the brains were dissected on ice. The tissue samples 
157 
(hippocampus and septum) were immediately placed on dry ice 
and subsequently stored at -7o0c. 
Enzyme Assays 
Tissue preparation 
The tissue (septum and hippocampus) was thawed in ice 
cold sodium phosphate buffer 75 rn.M, pH 7.4, (1 ml for 
hippocampus and 0.6 ml for septum) and homogenized (20 sec. 
@ setting 5 on a Polytron homogenizer model # PT 10/35) . The 
septal and hippocampal tissue homogenates were then divided 
into two aliquots, one for the ChAT and AChE assays and the 
other for the GAD assay. The ChAT/AChE homogenate was frozen 
at -70°C until the assays were conducted. To the GAD 
homogenate, 0.1% Triton XlOO and 2.5 mM 
aminoethylisothiouronium bromide in 100 mM potassium 
phosphate buffer (pH 7.2) was added. 
GAD activity 
Glutamic acid decarboxylase activity was determined by 
[ 3H]GABA formation and cation exchange isolation (Maderdrut 
1979). Twenty micro liters of tissue homogenate was added to 
30 µl of buffer substrate containing: 500 µM, EDTA tetra-
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sodium salt hydrate; 200 µM, pyridoxal-5'-phosphate; 12 mM, 
glutamic acid and 10 mM, GABA in potassium phosphate buff er 
(pH 7.2, 100 mM). This solution was spiked with [3H] 
glutamic acid for a specific activity of 0.27 µCi per assay. 
The blanks, used to define non-specific activity, consisted 
of tubes containing 20 µl of buff er substituted for the 
tissue homogenate. The samples were incubated for 30 minutes 
at 37°C and then placed on ice. Five hundred micro liters of 
5% trichloroacetic acid was added and the tubes were 
vortexed. The samples were loaded into columns containing 
4 cm of 50W-X4 cation exchange resin (Bio-Rad Laboratories) 
which had been equilibrated with 4 ml of 2N NaOH followed by 
5 ml of 0.2M citric acid. In order to remove any non-
specific bound [3H] glutamic acid, the columns were washed 
with 9 ml of cold sodium citrate buffer (0.2M, pH 3.5) and 
then [3H] GABA was eluted by the addition of 4 ml of cold 
sodium acetate (0.2M, pH 5.5) to the column. The eluate was 
collected into scintillation vials and 12 ml of scintill-
ation cocktail was added. The vials were counted and the 
amount of specific activity was determined by subtracting 
the dpms in the blanks from those in the samples. 
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ChAT activity 
The ChAT assay followed the Fonnum method (1975). In 
brief, 10 µl of tissue homogenate was added to 10 µl of 
buffer substrate [cold sodium phosphate, 75 mM pH 7.4; NaCl, 
600 mM; MgC1 2 , 40 mM; eserine, 2.0 mM; bovine serum albumin, 
0.05%; choline-iodide, 10 mM; and [3H]acetyl coenzyme A, 
0.87 mM (= 20 mCi/mmol)]. This mixture was then incubated 
for 30 minutes at 37°C and the tubes placed on crushed ice 
following incubation. One hundred and fifty microliter of 
sodium tetraphenylboron solution (75 mg/ml in 3-heptanone) 
was added to each tube and the tubes were vortexed and 
centrifuged. After centrifugation, 100 µl of the organic 
(top) layer was removed and placed into scintillation vials. 
Ten milliliters of scintillation cocktail was added and the 
vials were counted using liquid scintillation spectrometry. 
The level of ChAT activity was measured by subtracting the 
disintegrations per minute (dpm) in the blank tubes (without 
tissue) from the dpm in the tubes with tissue. 
AChE activity 
The AChE assay is similar to the ChAT assay, but with 
the following modifications (Leventer et al. 1985). Tissue 
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homogenate (10 µl) was added to 20 µl of buffer substrate 
[cold sodium phosphate buffer, 75mM, pH 7.0; AChI, lOmM and 
[ 3H]ACh iodide 10 mM (= 8 mCi/mmol)]. This mixture was 
incubated for 20 minutes at 37°C and the tubes were then 
placed into crushed ice. Ice cold water (30 µl) was then 
added to each tube followed by 150 µl sodium tetra-
phenylboron solution (75 mg/ml in 3-heptanone) . The tubes 
were then vortexed, centrifuged, and frozen for 30 minutes 
at -20°C. When removed from the freezer the organic (top) 
layer was discarded and the aqueous (bottom) layer thawed. 
Thirty micro liters of this aqueous layer was placed into 
scintillation vials and 10 ml of scintillation cocktail was 
added. These vials, along with blank tubes (without tissue 
substrate) , were counted using a liquid scintillation 
spectrometer. The level of AChE activity was calculated by 
subtracting the dpm in the blank tubes from the dpm in the 
assay tubes with tissue. 
Protein Determination 
Tissue protein levels were assessed by the method of 
Lowry et al., (1951) for all three assays. 
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Statistical Analysis 
The levels of enzyme activity in the rats are 
expressed as nmol/mg/hour. The values indicated in the text 
and figures are means ± SEM. The data were analyzed by ANOVA 
followed by post-hoc analysis (Fisher LSD) . Changes in the 
weight of the rats are expressed as the % mean ± SEM of the 
rats' initial weight and these data were analyzed by 
repeated measures ANOVA. 
Results 
Enzyme Activity in Normal Rats 
Cholinergic and GABAergic enzyme activities were 
assessed in normal rats treated by i.c.v. injection with 
various doses of BDNF (0.099-99 µg; 0.008-8 nmol total 
administered continuously over 14 days). In the hippocampus, 
ChAT, AChE, and GAD activity remained unchanged after BDNF 
administration (f= 1.03, p=0.404, df=4; f=2.26, p=0.083, df= 
4; f=l.34, p=0.276, df=4 respectively) (figs. 27, 28, 29). In 
the septum, there was a slight, but non-significant, 
increase in cholinergic enzyme activity (f=0.29, p=0.537, 
df=4 for ChAT and f=l.00, p=0.42, df=4 for AChE) (figs. 27, 
28) . 
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Fig. 27. Dose response of BDNF in normal rats. BDNF or CC 
(8 nmol) was infused i.c.v. over 14 days. Each point 
represents the mean ± SEM of 7-8 rats per treatment group. 
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Fig. 28. Dose response of BDNF in normal rats. BDNF or CC 
(8 nmol) was infused i.c.v. over 14 days. Each point 
represents the mean ± SEM of 7-8 rats per treatment group. 
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Fig. 29. Dose response of BDNF in normal rats. BDNF or CC 
(8 nmol) was infused i.c.v. over 14 days. Each point 
represents the mean ± SEM of 7-8 rats per treatment group. 
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GAD activity in this region was unaltered by BDNF (f=0.639, 
p=0.639, df=4) (fig. 29). 
Enzyme Activity in AF64A Treated Rats 
Enzyme activity was assessed in the SHP of rats 
initially treated with either VEH or AF64A, and then with 
either CC (8.0 nmol) or BDNF (0.008-8.0 nmol over 14 days). 
In the hippocampus, there was no significant change in ChAT 
activity (f=l.84, p=0.128, df=5). AF64A/CC treatment 
produced a non-significant, 27% reduction in hippocampal 
ChAT activity. AF64A/BDNF treated rats did not show any 
increase in hippocampal ChAT activity. This activity 
remained decreased by 45% and 19~ of control for 0.008 and 
8.0 nmol BDNF respectively (fig. 30). In the septal region, 
there was a significant change in ChAT activity (f=S.32, 
p=0.001, df=S). Septal ChAT activity in AF64A/CC treated 
rats was similar to control levels. At the two highest doses 
of BDNF (0.8 and 8.0 nmol), septal ChAT activity was 
significantly (p< 0.01) increased 126% of control for both 
doses (fig. 30). 
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Fig 30. Rats were treated by i.c.v. injection with either 
VEH (water) or AF64A (1.5 nmol/ventricle) followed by i.c.v. 
infusion of either CC (8 nmol} or BDNF (0.008-8 nmol). Rats 
were treated with CC or BDNF for 14 days. The data represent 
the mean ChAT activity± SEM of 7-8 rats per group. *, 
p< 0.05 compared with VEH/CC; and **, p< 0.01 compared with 
AF64A/CC treated rats. 
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In addition, these increases were significantly (p< 0.05) 
greater than those in rats treated with lower doses of BDNF 
(0.008 and 0.08 nmol) and indicates that BDNF affects ChAT 
activity in a dose-dependent manner. 
Hippocampal AChE activity was significantly altered in 
the AF64A dose response experiment (f=6.304, p=0.000 df=5). 
AChE activity in the hippocampus was significantly reduced 
(41% of control) by AF64A/CC and remained decreased over all 
four doses of BDNF (fig. 31). In the septum, AChE activity 
was not significantly increased by treatment with either 
AF64A/CC nor any dose of AF64A/BDNF (f=0.891, p 0.497, 
df=5) (fig. 31). 
Hippocampal GAD activity was unchanged by either 
AF64A/CC or AF64A/BDNF treatment (f=l.081, p=0.386, 
df=5) (fig. 32). GAD activity in the septum of AF64A/CC or 
AF64A/BDNF treated rats was unchanged (f=2.155, p=0.080, 
df=5) (fig. 32). 
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Fig. 31. Rats were treated by i.c.v. injection with either 
VEH (water) or AF64A (1.5 nmol/ventricle) followed by i.c.v. 
infusion of either CC (8 nmol) or BDNF (0.008-8 nmol). Rats 
were treated with CC or BDNF for 14 days. The data represent 
the mean AChE activity ± SEM of 7-8 rats per group. 
*, p< 0.05 compared with VEH/CC. 
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Fig. 32. Rats were treated by i.c.v. injection with either 
VEH (water) or AF64A (1.5 nmol/ventricle) followed by i.c.v. 
infusion of either CC (8 nmol) or BDNF (0.008-8 nmol). Rats 
were treated with CC or BDNF for 14 days. The data represent 
the mean GAD activity ± SEM of 7-8 rats per group. 
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Attenuation in Weight Gain of BDNF Treated Rats 
In both experiments, rats were weighed at the time of 
surgery and then once every week. Weight gain was altered 
significantly in both normal (f=3.23, p=0.026, df=4) and 
AF64A (f=3.42, p=0.012, df=S) treated rats which were 
administered BDNF (Table 6). Normal rats treated with 8.0 
nmol BDNF had a 4% reduction in weight over 14 days while 
the control rats had a 32% weight gain. AF64A/BDNF (8.0 
nmol) treated rats lost weight (5~) over the 14 day 
treatment period compared with control rats (VEH/CC) which 
had a 16% gain in their weight. AF64A/CC treatment did not 
attenuate weight gain since these rats had increases in 
their weight comparable to controls (table 6) . 
Discussion 
The present work demonstrates that in vivo 
administration of BDNF into the lateral ventricle of normal 
non-AF64A treated rats does not alter cholinergic enzyme 
activity in the SHP. This is in agreement with work that 
showed that, i.c.v. administration of BDNF did not alter 
ChAT activity in normal rats (Koliatsos et al. 1994). 
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Table 6.-- Changes in the weight of both normal and AF64A 
treated rats. 
TREATMENT WEIGHT-DAY 7 WEIGHT-DAY 14 
cc 107 ( 3. 68) 132 (3.69) 
BDNF 0.008 110 ( 3 . 22) 136 (3.64) 
BDNF 0.08 113 ( 4. 77) 138 ( 3 . 94) 
BDNF 0.8 97 (5.21)* 104 (5.34)** 
BDNF 8 88 (13.01)*'1< 96 (5.61)** 
VEH/CC 101 ( 6 .48) 116 (7.10) 
AF64A/CC 104 ( 4. 71) 117 (7.52) 
AF64A/BDNF 0.008 112 ( 3. 26) 122 (4.07) 
AF64A/BDNF 0.08 108 (3.80) 122 (4.28) 
AF64A/BDNF 0.8 101 (5.23) 111 ( 6. 96) 
AF64A/BDNF 8 89 ( 5. 35) 95 (5.83)a 
Rats were administered (i.c.v.) CC (8 nmol) or various 
doses of BDNF. The mean ± SEM of the % of the initial 
weight at the time of surgery are indicated. The top half 
of the chart represents BDNF treatment in the normal rats 
and the bottom half represents those treated with AF64A. * 
P< 0.05 VS Cytochrome C; ~*, p < 0.01 vs CC; a, p < 0.01 VS 
VEH/CC. 
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Further, the data in the present study are in contrast to 
the stimulation of septal and hippocampal ChAT activity 
produced by NGF in normal rats (Willson and Hanin, in press; 
Fusco et al. 1989). These data indicate that doses of BDNF 
higher than those used in the present study may be necessary 
to stimulate normal cholinergic neurons in the SHP. 
The data in the present study indicate that cholinergic 
neurons of the SHP may be more sensitive to BDNF after AF64A 
treatment. In AF64A treated rats, i.c.v. BDNF administration 
at doses of 0.8 and 8 nmol produced a significant increase 
in septal ChAT activity. These results are similar to those 
in AF64A/NGF treated rats where septal neurons were found to 
be more responsive to NGP after AP64A treatment (Willson and 
Hanin, in press) . Although similar doses of NGF and BDNF 
(10 µg each; 0.76 and 0.8 nmol respectively) increase 
cholinergic enzyme activity in septal neurons, these neurons 
are more responsiveness to NGF (Willson and Hanin, in 
press) . Neurons in the septal region of FF transected rats 
are also more responsive to NGF than BDNF, when similar 
doses are administered (Morse et al. 1993; Knusel et al. 
1992) . In addition, dose response experiments in septal 
cultures with NGF and BDNF have shown that NGF is 90 times 
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more potent than BDNF in increasing ChAT activity (Knusel et 
al. 1992). 
AF64A/CC treatment did not alter septal cholinergic 
enzyme activity at the 14 day time point used in the present 
study. El Tamer et al. (1992) has shown that AF64A produces 
increased septal ChAT activity three to seven days after 
AF64A administration and that the level of enzyme activity 
returns to normal by 14 days. These data indicate that the 
increase in ChAT activity in the septum of AF64A/BDNF 
treated rats was due to the action of BDNF on these neurons 
and not the stimulation of enzyme activity by AF64A. 
AF64A/CC treatment produced a non-significant reduction 
in the cholinergic enzyme activity in the hippocampus. Since 
the action of AF64A is dose-dependent (El Tamer et al. 
1992), the immediate infusion of BDNF into the ventricle 
after AF64A injection may have possibly diluted the dose of 
AF64A received by the rat. The 27~ reduction in ChAT 
activity is similar to the decrease in enzyme activity in 
rats treated with lower doses of AF64A (El Tarner et al. 
1992) . 
Cholinergic enzyme activity in AF64A in treated rats 
was not stimulated by i.c.v. administration of BNDF. In 
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contrast, previous work has shown that other NTFs, such as 
bFGF (Potter and Morrison 1991), as well as vitamin E, can 
reverse AF64A induced decreases in cholinergic enzyme 
activity (Johnson et al. 1988; Wortwein et al. 1994). 
Further, in vivo BDNF administration can protect against 
cholinergic neuronal atrophy in the septum that occurs after 
FF transection (Knusel et al. 1992; Morse et al. 1993). 
The data from the present study indicate that BDNF 
administered by i.c.v. infusion did not affect GABAergic 
neurons. Even at doses of BDNF that increased septal ChAT 
activity, GAD activity in the SEP was not changed in 
AF64A/BDNF treated rats. Previous work has demonstrated that 
BDNF does not alter GAD mRNA in the medial septum of FF 
transected rats (Koliatsos et al. 1994). In contrast, 
supranigral infusions of BDNF increase GAD activity in the 
superior colliculus (Altar et al. 1994a) but, do not alter 
GABA uptake in the striatum of 6-0HDA lesioned rats (Altar 
et al. 1994b). Although BDNF does not appear to interact 
with GABAergic neurons, it does interact with dopaminergic 
and serotonergic neurons of the nigrostriatal pathway (Altar 
et al. 1994a; Altar et al. 1994b). The action of BDNF on 
several neurotransmitter systems, as well as the 
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localization of its mRNA (Ernfors et al. 1990a; Phillips et 
al. 1990) and receptor (Yan et al. 1994; Altar et al. 
1994c) , indicate that BDNF may act on multiple neuronal 
populations. 
In the present work, BDNF administration attenuated 
normal weight gain in these rats. This inhibition of weight 
gain was dose-dependent since rats administered lower doses 
of BDNF (0.008 and 0.08 nmol) did not have a reduction in 
the amount of weight they gained over the course of the 
experiment. The attenuated weight gain was not due to AF64A 
treatment since normal rats treated with BDNF also had an 
attenuation in weight gain. The changes in weight gain have 
been postulated to be due to the direct action of BNDF on 
TrkB receptors located in the hypothalamus (Lapchak and 
Hefti 1992; Altar et al. 1994c). The changes in weight gain 
in BDNF treated rats in the present study are similar to 
those seen in NGF treated rats (Lapchak and Hefti 1992). 
In conclusion, septal cholinergic neurons of AF64A 
treated rats have an increased sensitivity to exogenously 
administered BDNF. BDNFs action in the SHP of AF64A treated 
rats is not a generalized effect on neuronal activity since 
enzyme activity in GABAergic neurons is unaltered by BDNF. 
CHAPTER VII 
DISCUSSION 
NTFs represent a relatively new group of proteins which 
have been postulated to have future potential as therapeutic 
agents in the treatment of neurodegenerative diseases. The 
in vivo data in the current work increase our understanding 
of the effects of NTFs in normal rats as well as those with 
reduced cholinergic phenotypic markers. In the present work, 
two hypotheses were tested: 1) exogenous NTFs, when admin-
istered in vivo to adult rats, stimulate ChAT and AChE 
activity in normal cholinergic neurons; and 2) when 
alterations in neuronal cholinergic enzyme activity are 
created by AF64A, the effected neurons have an increased 
sensitivity to exogenous NTF administration. In order to 
address these two hypotheses, two specific aims were 
formulated. The first specific aim was to study the effect 
of i.c.v. administration of NGF and BDNF on normal chol-
inergic neurons of the SHP. NGF increased ChAT activity in 
the hippocampus and septum by l42% and 149% of control, 
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respectively. Changes in hippocampal activity occurred in a 
dose-dependent manner. Further, i.c.v. administration of NGF 
over 3, 7, 14 and 28 days produced increased ChAT activity 
after seven days of administration. In contrast, BDNF, at 
the doses used in the present work, did not alter cholin-
ergic enzyme activity in the SHP of normal rats. This 
suggests that normal cholinergic neurons of the SHP respond 
differently to various NTPs. Neither NGF nor BDNF increased 
AChE activity in the SHP of normal rats indicating that, 
ChAT and AChE are differentially affected by NGF in normal 
rats. 
The change in ChAT activity, induced by NGF, in normal 
rats appears to be limited to cholinergic neurons and is not 
a generalized phenomenon. This was evident from the 
inability of NGF or BDNF to alter the level of GAD activity 
in normal rats and suggests that GABAergic neurons of the 
SHP are not sensitive to exogenous BDNF or NGF. 
The second specific aim in the present work was 
designed to investigate the effect of AF64A treatment on the 
ability of in vivo NTF administration to alter cholinergic 
enzyme activity in neurons of the SHP. This specific aim 
addressed the question of whether AF64A treatment increases 
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the sensitivity of cholinergic neurons in the SHP to 
exogenous NTFs. In these experiments, the action of NGF, 
BDNF, and bFGF on cholinergic enzyme activity in the septum 
and hippocampus of AF64A treated rats was evaluated. In 
addition, the action of NGF and BDNF on GAD activity in the 
SHP of AF64A treated rats was evaluated. 
In AF64A/NGF treated rats, AF64A treatment produced a 
increased response in septal cholinergic enzyme activity NTF 
administration. The response in AF64A treated rats to NGF 
was greater (273%) than in normal, NGF treated rats (149%) 
Septal cholinergic neurons in rats treated with AF64A also 
demonstrated increased sensitivity to exogenous BDNF. The 
increase in ChAT activity in these rats was less than in NGF 
treated rats even though, the doses of BDNF used were 
higher. In contrast, bFGF did not produce any increase in 
cholinergic enzyme activity in the SHP of AF64A treated 
rats. These data indicate that cholinergic neurons of the 
septum are not as responsive to bFGF as they are to the 
other two NTFs used in this work. 
Other studies have also shown that rats with reduced 
cholinergic phenotypic markers are more sensitive to NGF. 
Rats with complete FF transections are "supersensitive" to 
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NGF (Williams, Jodelis and Donald 1989). NGF increased ChAT 
activity to a level 200% higher in FF transected rats than 
in normal rats treated with NGF. This increase in sensi-
tivity, as well as those in the current work, may be due to 
the stimulation of endogenous NTPs. Lesioning the septum 
increases endogenous NGP-like biological activity in the 
hippocampus (as determined by bioassay, Scott et al. 1994). 
FF transection produces an increase in hippocampal and 
septal NGF (Weskamp et al. 1986). Further, chemical 
substances, such as kainic acid, increase hippocampal NGF 
mRNA expression (Gall, Murray and Isackson 1991). The 
possibility therefore exists that AP64A treatment may 
stimulate the production of endogenous NGF. An experiment 
determining whether AP64A alters the endogenous level of NGF 
or its mRNA would address this question. 
The increase in cholinergic enzyme activity by NTFs in 
the SHP of both normal and AF64A treated rats is probably 
due to the stimulated production of mRNA for cholinergic 
enzymes. NGF has been shown to increase ChAT mRNA levels in 
the basal forebrain of normal rats (Cavicchioli et al. 1991; 
Li et al. 1995). AF64A treatment increases both ChAT mRNA 
(Fan et al. 1995) and ChAT activity in the septum (El Tamer 
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et al. 1992). An increase in ChAT mRNA by AF64A, coupled 
with increases produced by NGF, may account for the overall 
increased level of ChAT activity in the septum of AF64A/NGF 
treated rats in the present study. Experiments evaluating 
changes in ChAT mRNA after AF64A/NGF treatment are required 
in order to address this issue. 
NGF treatment in AF64A treated rats produced recovery 
in cholinergic enzyme activity after 28 days of continuous 
NGF treatment. At this length of treatment, NGF administra-
tion increased enzyme activity to control levels. When 
administered over 14 days 1 neither BDNF nor bFGF produced 
any recovery of cholinergic enzyme activity in the hippo-
campus of AF64A treated rats. These two NTFs will have to be 
tested over longer lengths of administration than used in 
the current study before dismissing them as agents that can 
reverse decreased enzyme activity. 
AF64A treated rats are known to have working memory 
deficits (Chrobak et al. 1987; Chrobak et al. 1988). NGF has 
been shown to reverse memory deficits in aged rats and 
therefore may also reverse behavioral changes induced by 
AF64A (Fischer, Wictorin, and Bjorklund 1988). A future 
experiment could evaluate whether rats treated with 
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AF64A/NGF have any behavioral changes compared with AF64A/CC 
treated rats. 
NTFs have been previously proposed for the treatment of 
neurodegenerative diseases. In vitro and in vivo work in 
animals indicates that NTFs can reverse decreased neuronal 
markers in several anatomical regions. NGF has been shown to 
be important for cholinergic neurons of the basal forebrain 
(Montero and Hefti, 1988; Hagg et al. 1989; Kromer 1987), an 
area where decreased levels of cholinergic markers occur in 
SDAT patients (Whitehouse et al. 1982; West et al. 1994). 
NGF infusion into the lateral ventricle of a SDAT patient 
has already been conducted. NGF was found to produce 
recovery in nicotinic receptor binding in the frontal cortex 
as well as improve performance on memory tasks (Olson et al. 
1991). Although these results were promising, treatment had 
to be discontinued due to pain experienced by the patient. 
An additional drawback to the use of NTFs as therapeutic 
agents is the issue of whether they produce any aberrant 
neuronal growth which may be detrimental to neuronal dis-
tribution and innervation. Further experiments will have to 
be conducted in order to evaluate whether harmful growth 
occurs with in vivo NTF administration. 
BDNF appears to also act on the dopaminergic system. 
Studies with BDNF in rats treated with 6-0HDA demonstrate 
that BDNF can produce a recovery in behavior and dopamin-
ergic function (Altar et al. 1994b). Therefore, BDNF may 
provide a useful tool in the treatment of Parkinson's 
disease (Lindsay et al. 1993). This diversity of action 
indicates that NTFs may be important in a wide range of 
neuronal systems but, that some specificity occurs. 
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The data from the present study indicate that bFGF may 
not represent a promising therapeutic agent in neuro-
degenerative diseases. The lack of effect of bFGF in AF64A 
treated rats compared with other NTFs (NGF and BDNF) suggest 
indicate that this growth factor may act by a mechanism 
different from that of NGF or BDNP. 
In conclusion, the present work indicates that AF64A 
treatment produces an increased responsiveness in cholin-
ergic neurons to exogenous NTFs. The mechanism of this 
increased sensitivity remains to be determined. 
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